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Abstract 
Covering the metal surface of blood-contacting cardiovascular implants (stents, 
ventricular assist devices) with functional endothelium may reduce the incidence of 
clotting and restenosis complications and also reduce the need for risky anticoagulation 
therapy following implantation of such devices.  We developed a novel cell therapy for 
seeding autologous endothelium onto blood-contacting vascular stents at the point of 
care to reduce thrombosis and stent restenosis.  The proposed research tested the 
following hypotheses:  (1) autologous endothelial cells (ECs) can spread on titanium (Ti) 
tubes and reduce thrombosis on the Ti surface in vivo; (2) shear stresses on the surfaces 
of an implanted carotid artery stent will be conducive to EC retention and function 
under arterial flow; and (3) nitinol stents seeded with ECs at the point of care will 
remain adherent and functional after stent deployment and arterial fluid shear stress 
conditions in vitro and in vivo.  Based on the experiments reported herein, the primary 
conclusions of the dissertation are as follows:  (1) autologous ECs  significantly reduce 
thrombosis on Ti surfaces implanted into the bloodstream in vivo; (2) shear stresses on 
stent surfaces under carotid artery flow conditions are sufficiently low to be compatible 
with EC retention and function; (3) ECs seeded onto nitinol stents by infusion at the 
point of care are retained and spread to form a functional layer following deployment 
and arterial flow conditions both in vitro and in vivo. 
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1. Background, significance, specific aims, and 
hypotheses 
1.1 Background and significance 
1.1.1 Clinical need for and use of nitinol stents 
Atherothrombotic diseases are projected to be the leading cause of death 
worldwide in 2020[1].  Two specific subcategories of atherosclerotic disease, peripheral 
vascular disease and coronary artery disease, are commonly treated by stents. 
1.1.1.1 Peripheral artery disease 
Peripheral arterial disease (PAD) affects approximately 8.5 million people in the 
United States[2], including 12-20% of individuals over the age of 60[3].  The most severe & 
deadly form of the disease, critical limb ischemia, affects an estimated 2.8 to 3.5 million 
PAD patients nationally[4].   
Angioplasty and stenting of the small vessels in the leg, particularly below the 
knee, is a frequently used technique for limb salvage.  By one estimate, 300,000 stents are 
placed each year in peripheral arteries in the United States[5].  However, stents in vessels 
less than 5 mm in diameter suffer from high rates of restenosis resulting from intimal 
hyperplasia and thrombosis[6].  Drug-eluting stents are coated with anti-proliferative 
compounds such as sirolimus and paclitaxel and aim to reduce intimal hyperplasia.  
Such compounds nonspecifically reduce proliferation of both smooth muscle and 
endothelium.  Drug-eluting stents represent a potential solution to restenosis, but are 
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still associated with serious complications and late thrombosis in a number of patients[7].  
Longer-term delivery of paclitaxel to stainless steel stents has been achieved in animal 
studies by magnetic targeting[8,9], but is not applicable to self-expanding nitinol stents 
used in peripheral vasculature because they are significantly less ferromagnetic[10].   
1.1.1.2 Coronary artery disease 
Coronary artery disease has a large impact in our society; it was the cause of 1 
out of 6 deaths in the United States in 2010[2].  An estimated 15.4 million Americans over 
age 20 have coronary disease[2], which is approximately double the number of people 
affected by peripheral arterial disease. The primary endpoint in peripheral arterial 
disease is often amputation, indirectly associated with mortality rates.  In contrast, 
coronary artery disease is associated more directly with myocardial infarction and 
mortality.  The estimated annual incidence of myocardial infarction in the United States 
is 620,000 new attacks and 295,000 recurrent attacks[2].  The lifetime risk of developing 
coronary heart disease after 40 years of age is 49% for men and 32% for women[11], 
according to one population study.   
Angioplasty and stenting of coronary vessels and coronary grafts is a frequently 
used treatment for coronary artery disease.  Approximately 650,000 cases of coronary 
stenting were performed in 2009 in the U.S., of which 75% were drug-eluting stents and 
25% were bare metal stents[12].  In comparison to the traditional surgical approach of 
coronary artery bypass grafting (CABG), stenting has been associated with significantly 
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lower rates of stroke[13] but higher rates of restenosis requiring repeat revascularization.  
Another prospective study concluded that stenting had equivalent outcomes at 1-2 years 
to CABG[14], with the benefit that it is a less invasive procedure and therefore may be 
suitable for some patients who are not candidates for surgery. 
 As with peripheral vascular disease, drug-eluting stents in coronary applications 
are associated with late-stage thrombosis.  This thrombosis is thought to be caused by 
either the polymer drug carrier or by incomplete formation of a protective endothelial 
layer[3,15].  Long-term patency rates are also negatively impacted by the small diameter of 
coronary vessels and stented bypass grafts[16]. 
1.1.1.3 Nitinol stents for vascular disease 
Two kinds of stents are used in the treatment of atherosclerosis: (1) balloon-
expanded stents, and (2) self-expanding stents.  Balloon-expanded stents are mounted 
onto balloons and forcefully expanded by inflation of the balloon; these stents are often 
made of stainless steel or cobalt chrome alloys.  Self-expanding stents, on the other hand, 
are delivered compressed inside a delivery sheath and expand to the final diameter 
when the sheath is retracted.  These have the advantage of greater flexibility.  Self-
expanding stents typically require the use of nitinol. 
Nitinol, a nickel-titanium alloy developed in the 1960’s[17], is used extensively in 
medical devices, especially implants.  The flexibility of nitinol is 10-20 times greater than 
stainless steel[18], meaning that nitinol stents conform very well to tortuous vessels.  
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Nitinol can be strained 20 times more than stainless steel without being plastically 
deformed[19].  Nitinol stents are typically cut from a single piece of tubing, then 
incrementally expanded and “set” to a desired final diameter through heat treatment.  
With a transition temperature for full expansion just below body temperature, nitinol 
stents will partly expand if unsheathed at room temperature, but will not reach their 
fully expanded set diameter unless warmed to body temperature.  This property is 
termed “shape memory.” 
The shape memory of nitinol means that these self-expanding stents can rebound 
in response to external pressures with continued radial force[18], unlike stainless steel 
stents, which would be crushed.  These important properties have led to the nearly 
exclusive use of nitinol self-expanding stents over balloon-expandable stents in 
superficial peripheral sites such as carotid and femoral arteries[20].  Superficial sites are 
not only subject to external compression, but vessels in the lower extremities are also 
subject to many forces from ambulation, subjecting stents to bending, torsion, and axial 
fatigue[21].  The superelastic properties of nitinol make nitinol stents well-suited to 
withstand these forces. 
More recently, a nitinol coronary stent has been introduced clinically with the 
aim of improving stent-vessel apposition and reducing distal embolization in 
comparison to balloon-expandable coronary stents[22,23].  The therapy proposed herein for 
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study therefore has a wide potential application in both peripheral and coronary artery 
diseases. 
1.1.1.4 The outer surface of nitinol consists primarily of TiO2 
When nitinol began to be used for medical implants, concerns about nickel on the 
surface and leaching from the implant had to be addressed.  Nitinol readily forms a TiO2 
layer on its outer surface, but residual nickel content is somewhat dependent on 
polishing and heat treatment techniques[24].  The process of electropolishing, standard for 
marketed self-expanding stents, significantly decreases the Ni on the outer surface[25].  
These facts support the idea that uncoated nitinol stents can support the growth of 
endothelial cells as we have seen previously with titanium[26,27], and that those studies 
can be related to the proposed work, although surface characterization is necessary to 
show similarity. 
1.1.2 Effectiveness of nitinol stents and drug-eluting stents in 
peripheral arterial disease and coronary arterial disease 
In peripheral arterial disease, restenosis occurs in 40-60% of femoral artery 
segments treated by balloon angioplasty alone after one year[28-30].  These rates are worse 
for extended disease segments; restenosis at one year is in excess of 70% for lesions over 
100mm[31].  Bare metal stents have lower rates of restenosis than angioplasty in the 
superficial femoral artery, ranging from 24% to 8% at six months in one set of studies[7,32].  
With drug-eluting stents for the superficial femoral artery, some clinical studies showed 
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reduced 12-month restenosis rates compared to bare metal stents (11% vs. 27%)[33], while 
another study showed no significant difference between drug-eluting and bare metal 
stents (22% vs. 21% at 24 months, respectively)[7].  Importantly, all studies found that 
restenosis occurred in a portion of the population after 6-12 months, supporting the 
claim that there is an unmet need and room for improving the outcomes of existing stent 
therapies. 
In coronary artery disease, restenosis is also an important concern; data show 
that in-stent restenosis has a negative impact on long-term patient survival[34].  Balloon 
angioplasty in coronary lesions is associated with a restenosis rate of over 40%[35].  In 
comparison, the addition of stents improved outcomes; however, the restenosis rates in 
coronary lesions treated with bare metal stents range from 20% to 40%[36]. 
1.1.2.1 Drug-eluting stents 
Drug-eluting stents (DES) have been in clinical use for coronary arteries longer 
than in peripheral applications, and reported rates of restenosis and late-stage 
thrombosis vary widely according to the stent platform, active drug, and polymer drug 
carrier.  Reported restenosis rates at 12 months are reduced over bare metal stents, at 
approximately 6%[37,38].  However, the delayed healing associated with drug-eluting 
stents is suspected of causing late-stage thrombosis in conjunction with patients’ 
scheduled decrease in anticoagulant and antiplatelet therapy and final release of the 
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drug coating[39,40].  Late-stage thrombosis is typically described as occurring 6-12 months 
or more after stent placement. 
A variety of drugs are approved for use in DES.  The drugs used in 
contemporary DES can be divided into two categories:  1) Rapamycins, including 
sirolimus, zotarolimus, everolimus, and biolimus A9; and 2) Taxanes, including 
paclitaxel.  Drugs in both categories have their primary function as antiproliferative 
drugs.  Paclitaxel is used in other applications as a chemotherapeutic agent for cancer, 
because of its antiproliferative properties[41].  Rapamycin-type drugs have been used in 
other applications as an immunosuppressant to prevent rejection in organ 
transplantation[42], and are also associated with cancer inhibition[43]. 
Most current DES platforms consist of three components:  the physical stent 
scaffold, drug to inhibit neointimal hyperplasia, and a polymer to deliver the drug with 
a controlled release.  Polymers employed in drug-eluting stents have included biostable 
polymers, bioabsorbable polymers, and natural biopolymers[44].  Some polymers used in 
first-generation DES were associated with significant inflammation[45-47].  In second-
generation DES, results have shown some improvement in restenosis rates over first-
generation devices in some cases[48], but higher incidence of restenosis in others[49],  and 
no cases of very late stent thrombosis over 4 years in one stent platform[50].  Polymer 
degradation speed varies and is related to many factors including monomer 
hydrophilicity, polymer size, crystallinity, pH, and reactivity of hydrolytic groups[51].  
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While most DES make use of a polymer carrier, there are FDA-approved DES platforms 
which do not use a polymer carrier[52]. 
Endothelial dysfunction has been reported following drug-eluting stent 
implantation.  A review of the literature revealed abnormal vasoconstriction in distal 
vessel segments after implantation of sirolimus-eluting stents and paclitaxel-eluting 
stents, but not in zotarolimus-eluting stents or biolimus-eluting stents, compared with 
bare metal stents[53].  The vasoconstriction events were observed following a variety of 
different provocation tests, but it is unclear how this may be associated with a clinical 
outcome such as stent thrombosis or restenosis. 
1.1.2.2 Bioabsorbable stents 
An experimental alternative to permanent metal stent implants, bioabsorbable 
stents are made of materials like magnesium and poly-L-lactic acid[54,55].  Bioabsorbable 
stents fully resorb into the bloodstream after a period of time ranging from months to 
years.  The intent is that no lasting implant remains after this time.  Despite the appeal of 
a non-permanent implantable device, bioabsorbable stents have the disadvantage of 
lower radial strength compared to metal stents; methods used to increase the strength 
reduce the potential for bioabsorption.  It is not clear whether the vessel will remain 
patent following the absorption of the stent; results with a magnesium stent were 
disappointing and showed a 45% rate of restenosis at 4 months, close to the restenosis 
rates of angioplasty[54]. 
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A more recent trial of a poly-L-lactic acid stent, coated with poly-D,L–lactic acid 
to facilitate release of the antiproliferative drug everolimus showed more positive 
results, with restenosis rates and late lumen loss at 6-24 months similar to the current 
generation of drug-eluting stents[55].  This was attributed to rapid changes in stent 
integrity during absorption, highlighting the importance of the degradation profile.  
Only about 30% of the stent mass is absorbed after 12 months, and it is not clear whether 
patency outcomes will remain positive following full absorption.  A second generation 
version of this bioabsorbable stent device was investigated clinically, but reported 
slightly higher rates of late lumen loss and neointimal growth compared to the first 
generation device, and no improvement over metallic everolimus-eluting stents 
evaluated at the same time points[56].  Another polymeric bioabsorbable stent composed 
of poly(lactic-co-glycolic) acid and elastomer showed mild and stable levels of intimal 
hyperplasia in a pre-clinical ovine model[57].   
Although bioabsorbable stents aim to reduce late and very late complications, 
isolated cases of late stent thrombosis (2 years post-stenting) have still been reported 
with bioresorbable stents[58].  Increasingly, bioabsorbable stent platforms are also 
incorporating antiproliferative drugs; because these drugs inhibit endothelial growth, it 
will be critical that the drug release timescale is carefully adjusted to be compatible with 
the stent absorption timescale, so that endothelium covers the stent structure before bulk 
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erosion could occur; without this endothelial coverage, embolization of the degrading 
stent pieces is a possibility. 
1.1.3 Endothelialization of stents and titanium vascular implants 
Since the first clinical use of metal stents in the late 1980’s[59], patency rates have 
improved over those of balloon angioplasty alone, but restenosis remains a problem.  
Specific failure modes have been identified in the broad categories of thrombosis and 
intimal hyperplasia.  Intimal hyperplasia is characterized by over-proliferation of 
smooth muscle cells (SMC) in the media layer.  Commonly, intimal hyperplasia is co-
localized with disruptions of the internal elastic lamina layer of the media[60].  This 
physical injury to the vessel is an opportunity for locally delivered cells with reparative 
capability to improve hyperplasia outcomes.  Specifically, locally delivered endothelial 
cells could potentially release paracrine factors (e.g. nitric oxide), which inhibit SMC 
proliferation and subsequent intimal hyperplasia[61]. 
Given the importance of the endothelial layer and its anti-thrombogenic 
properties, researchers have attempted to cover metal stents with endothelial cells as 
early as 1988[62].  These studies have added to understanding of various cell sources and 
attachment methods, but none have provided a method which has led to 
general/widespread clinical use. 
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1.1.3.1 Pre-implantation seeding of stents 
Direct seeding of metal stents with ECs prior to implantation has been attempted 
using a variety of methods.  Limitations of these studies include use of immortalized or 
xenogeneic cell sources[63,64], pre-coating of the stent with protein or polymer[62,65-68], and 
prohibitively long culture of the stent and cells together[64-67]. 
ECs do not adhere and grow on stents manufactured from stainless steel and 
other metals as they do on titanium; consequently, some researchers have utilized pre-
coating techniques with protein or polymer to promote adhesion of cells to these metals. 
Previously investigated coatings include heparinized lactone polymer[65], photocured 
gelatin[66], fibrin gel[67], self-assembled guanine-cytosine nanotubes[69], poly-L-lysine[70], 
and fibronectin[62,68,70,71]. These coatings add complexity and potential complications; 
fibronectin coating, for example, promotes platelet adhesion and could lead to thrombus 
formation on any areas of the stent with incomplete EC coverage[62,68].   
Stent seeding methods used previously have largely consisted of culturing cells 
together with stents, with periodic rotation of the stent around its long axis to achieve 
even coverage. The seeding processes described are extended, ranging from 1 hour at 
the shortest[64] to several hours[62,65,66,71] and up to 24 hrs[67]. Following initial seeding of 
cells to the stents, further culture was carried out in all of these studies to allow the 
endothelial monolayer to achieve confluence.  Prolonged culture time of the stent and 
cells together ranged from 2-3 days[65,67,71] to 7 days[66], or even 2 weeks[64].  Such extended 
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culture of cells with the device not only adds to the lead time required for the stenting 
procedure, but also presents issues and risks for maintaining sterility when translated to 
widespread clinical practice and regulatory approval.  This is of particular concern when 
considering that all methods presented here seeded stents in an expanded configuration.  
For simulated delivery, stents had to be subsequently clamped onto a balloon delivery 
catheter (in the case of balloon-expandable stents), or compressed into a restraining 
delivery sheath (in the case of self-expanding stents).  These extra manipulations are 
obviated by the proposed work. 
In the case of balloon expandable stents, the abrasion between balloon and stent 
during expansion was found to cause loss of most cells on the lumenal surface following 
balloon expansion[64,71], while other studies did not address the impact of stent 
deployment on ECs[65].  Although some studies showed almost no lumenal cell retention 
after balloon expansion, others assessed coverage at 10 to 70%[71]. 
As an alternative to incubating the stent with cells for multiple days, Kutryk et al. 
proposed infusing ECs through a simple angiographic catheter to the site of stenting 
following deployment[63], but did not present specifics on number of cells required or 
extent of coverage of the stent by ECs.  Another study delivered cells to a stent following 
deployment, but required 5-10 min cessation of flow in vivo.  This cessation of flow is 
impractical in a clinical setting, especially in coronary vessels[72].  That study, which 
employed magnetic labeling of cultured EPCs to target magnetically charged stents, 
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found good seeding efficiency and coverage of cells 24 hours after the catheter-based 
infusion of cells[72]; however, stainless steel stents were plated with nickel to achieve the 
necessary magnetic charge, and this is not a practical solution for long-term 
biocompatibility, or for self-expanding applications.  Nitinol stents did not retain 
sufficient charge to attract cells. 
1.1.3.2 “Capture stents” 
As an alternative to direct seeding, several strategies have been investigated to 
recruit circulating endothelial progenitor cells (EPCs) from the bloodstream.  Antibodies 
to CD34 have been attached to stents to capture circulating EPCs.  In porcine coronary 
arteries, these stents improved early endothelialization (2 and 5 days), but did not 
reduce neointimal hyperplasia at 28 or 90 days[73]. Clinical studies show that these 
“capture stents” are inferior to current DES[74], because the anti-CD34 antibodies were 
non-specific to ECs but also bound other cells, including hematopoietic stem cells and 
smooth muscle progenitor cells; this may result in increased neointimal 
proliferation[73,75].  At two year follow-up in clinical trials, a CD34-capture coronary stent 
showed no significant difference in target vessel failure compared to a paclitaxel-eluting 
coronary stent[76].  In clinical trials, a stent combining CD34 capture antibodies with 
sirolimus antiproliferative coating was also not significantly different from a paclitaxel-
eluting stent, with no difference in target lesion revascularization after12 months[77]. 
  
14 
 
Stents pre-coated with anti-VE-Cadherin (CD144) antibody were successful in 
capturing EPCs in healthy rabbits[78]; however, CD144 is also present on a portion of the 
more abundant early-outgrowth EPCs[79].  Surface-bound vascular endothelial growth 
factor (VEGF) exposed to the mononuclear fraction of blood in vitro caused an increase 
in VEGF-positive cells  adhered to the surface over time, but was not completely specific 
for endothelial-like cells[80].  Covering stents with cyclic Arg-Gly-Asp peptides (cRGD) 
reduced neointimal area and percent area stenosis at 12 weeks in a porcine model[81], but 
RGD binding sites are found on many other cells and plasma proteins[82], and are not 
specific to ECs.  Cobalt-chrome stents covered with Arg-Glu-Asp-Val (REDV) peptide in 
a rabbit iliac artery model showed a variety of cell types on the surface in addition to 
endothelium after one week, and showed no difference in endothelial coverage or 
degree of intimal hyperplasia compared to bare stents after four weeks[83]. 
A collagen matrix containing oligosaccharide sialyl Lewis X, which binds L-
selectin, increased the number of mobilized EPCs when injected into a rat hindlimb 
ischemia model[84], although specificity of capture from the bloodstream has not been 
presented.  Another capture strategy utilizing aptamers is under investigation but has 
not been tried in vivo and has not been shown to be fully specific to EPCs[85].  Because 
patients with diabetes or cardiovascular disease have greatly reduced number of 
circulating EPCs[86], capture stents may not be as effective as direct cell delivery, which 
adds the assistance of expansion in culture.   
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1.1.3.3 Potential advantages of catheter-based cell seeding proposal 
The proposed work avoids the problems of the previously described studies for 
seeding stents and capturing ECs from the blood stream.  This is accomplished by 
isolation, expansion, and seeding of ECs before implantation and deployment.  Further, 
the proposed work will eliminate the need to culture the stent and cells together for 
multiple days and manipulate the stent back into/onto a delivery catheter; instead, cells 
will be infused at the point of care.  Finally, the use of nitinol stents with their 
characteristic titanium oxide coating will obviate the need for additional and potentially 
thrombogenic coatings on the stent. 
1.1.4 Blood-derived endothelial cells – an autologous cell source 
Blood derived endothelial “progenitor” cells, first described by Asahara et al[87], 
are isolated from peripheral blood using methods described by Ingram et al.[88].  
Specifically, the “late outgrowth” EPCs (also called endothelial colony forming cells or 
endothelial outgrowth cells) function similarly to human aortic ECs, releasing 
vasodilators such nitric oxide (NO)[89,90] and preventing platelet adhesion[26].  We have 
previously characterized blood-derived ECs for markers and gene expression[90].  Late 
outgrowth EPCs are superior to the more abundant early outgrowth EPCs for the 
proposed therapeutic use, because of their higher proliferative capacity and ability to aid 
vascular repair[79].  Further, EPCs are noted for their natural ability to repair damaged 
vasculature[91].  Arterial injury in stenting is correlated with extent of neointimal 
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restenosis[92], leading to the idea that direct delivery of ECs to a site of stenting could 
accelerate repair and reduce restenosis caused by neointimal hyperplasia.  ECs seeded 
onto a stent have been shown to migrate into the surrounding tissue[66], further 
supporting this idea. 
The use of blood-derived endothelial cells grown out from endothelial 
“progenitor” cells for clinical vascular repair is appealing for multiple reasons.  Non-
autologous cells present obvious problems requiring matching and immunosuppression; 
other proposed solutions, such as transgenic porcine cells expressing human surface 
markers[63], have not been investigated clinically.  Sources of autologous ECs other than 
blood, such as digestion of saphenous or jugular veins[93], or adipose tissue 
microvasculature[94], require invasive surgical procedures.  The reprogramming of 
adipose-derived stem cells to express EC markers has been demonstrated[95], but the 
invasive harvest procedure remains prohibitive[96].  In contrast, blood-derived 
endothelial cells can be obtained through a routine blood draw.  Specifically, late 
outgrowth EPCs share many characteristics of adult endothelial cells[79].  It has been 
shown that EPCs can be isolated from coronary artery disease patients, and that these 
cells also express EC markers, proliferation potential, and produce nitric oxide[97].   
The number of EPCs circulating in peripheral blood has been shown to be 
significantly increased following the administration of the mobilizing agent AMD3100, 
typically used to mobilize hematopoietic stem cells in cancer patients[98].  We have also 
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shown the yield of EPCs can be increased ~4.5-fold with AMD3100 in our pig model.  
The availability and efficacy of this agent further supports the feasibility of ECs derived 
from circulating EPCs as a cell source.  
1.1.5 Modeling of shear stress on stents or ECs 
Computational modeling of stents has been used to examine deployment forces 
within the stent material[99], elution profiles of drug coated stents[100], and fluid shear 
stresses on vessel endothelium within a fully deployed stent[101-104].  Finite element 
analysis (FEA) of a stent has been used to examine stresses and strains within the bulk in 
a stent during deployment, identifying locations and magnitudes of stress and plastic 
deformation during balloon expansion[99].  FEA has also been used to examine the forces 
within an incrementally expanded nitinol stent before it is heat treated to its set 
expanded diameter[105].  Additionally, FEA can predict the overall stent foreshortening 
following deployment, as well as elastic recoil in balloon expanded stents[99].  Through 
comparison with experimental results, the predictive power of the computational 
analysis can be assessed[106].  Commonly, FEA is used to predict fatigue behavior of 
stents[107], thus informing stent design and supporting applications for regulatory 
approval before lengthy accelerated fatigue tests have been completed.  Nitinol stents 
intended for use in the superficial femoral or femoro-popliteal arteries are subjected to 
not only pulsatile fatigue, but also torsional and axial fatigue forces[21,108].  Rebelo et al. 
studied various computational methods for modeling pulsatile loading and patient 
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position on principal strains in a femoral artery stent[101].  Additionally, computational 
analysis has evaluated the release of drug into the lumen and into the arterial wall for 
drug-coated stents[100]. 
Computational modeling has also been used to examine fluid dynamics around a 
stent[100].  These studies seek to examine how a stent placed in an artery disturbs local 
flow patterns and imparts stress to the artery wall.  In a three-dimensional flow model 
including recirculation through a drug-coated stent in a coronary artery[100], drug 
distribution was affected by stent geometry and flow, and transient accumulation of 
drug occurred in the vessel downstream of the stent. Other computational studies 
showed that thinner struts, more aligned with the primary flow direction, decrease the 
effect of low wall shear stress on the arterial wall[109,110].  Low wall shear stress correlates 
with hyperplasia leading to restenosis[111-113] and areas of inhibited EC migration onto 
stents.[114].  Stent strut spacing has also been shown to have a strong effect on wall shear 
stress, flow stagnation and recirculation[102,103,115]. 
To date, little is known about fluid shear stresses on the surface of stents 
implanted in an artery; this has been of little interest without specific applications like 
adhesions of cells to the struts.  We are interested in these stresses as they affect EC 
retention in our stent seeding method, but also because transient gradients in shear 
affect EC function[116-118], important for future in vitro and in vivo studies.  We are also 
interested in the degree of flow reversal observed on various stent surfaces, because the 
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degree of flow reversal is known to affect EC phenotype and activation of inflammatory 
markers. 
1.1.6 Other applications of Ti in medical devices – VADs and their 
limitations 
In addition to nitinol stents, titanium is used in other cardiovascular implantable 
devices which contact the bloodstream.  Mechanical circulatory assist devices (MCADs) 
benefit heart failure patients as a bridge to transplant or a permanent destination 
therapy[119], with a potential for 250,000 patients annually[2].  Despite the benefits of 
MCADs, thrombosis and thromboembolic stroke cause significant morbidity and 
mortality for these patients.  The potential for endothelializing these devices is related to 
the proposed work, but will be limited in current generation devices by prohibitively 
high shear stresses in the majority of the device housing[120]. Only the outlet tube is 
expected to have sufficiently low shear stress to allow endothelialization.  While 
endothelializing this component may still have clinical utility and significance, and is 
under investigation in our lab as an extension of the methods of Aim 1, these MCAD 
applications will not be discussed in depth as part of this project. 
1.2 Specific aims and hypotheses 
The overarching goal of this project is to seed titanium cardiovascular implants 
with blood-derived endothelial cells (ECs) prior to implantation in order to reduce 
thrombosis and intimal hyperplasia.  This is valuable for stents and other Ti 
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cardiovascular devices, and we will investigate both stents and rigid Ti tubes.  We 
hypothesize that ECs seeded onto Ti blood-contacting surfaces minutes before 
implantation will create a confluent cell layer in vivo.  We also hypothesize that adhesion 
and function of ECs in a deployed stent will be influenced by the shear stresses during 
deployment and time of adhesion prior to deployment.  Specific Aims to address these 
hypotheses are: 
 
Specific Aim 1:  Optimize seeding of ECs onto Ti tube surfaces and characterize 
reduction of thrombus formation in swine.  Solid Ti tubes will be used to characterize 
the in vivo response of blood to bare titanium implants and implants seeded with 
autologous peripheral blood-derived ECs.  ECs -- derived from late outgrowth 
endothelial progenitor cells (EPCs) in pig blood -- will be seeded to the inner surface of 
Ti tubes by slowly rotating Ti tubes filled with a cell suspension.  Cell attachment and 
coverage after seeding will be evaluated to determine parameters necessary for optimal 
seeding; the goal is that ECs cover the surface when spread, without requirement for 
division.  Tubes will be implanted into the low shear stress environment of the vena 
cava and exposed to blood flow to evaluate the thrombosis response. 
Specific Aim 1 Hypotheses:  (1)  ECs seeded onto Ti blood-contacting surfaces 
minutes before implantation will create a confluent cell layer in vivo.  (2)  This treatment 
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will prevent thrombosis when inserted into the pro-thrombotic environment of the 
inferior vena cava (IVC) in swine. 
 
Specific Aim 2:  Determine fluid stresses on implanted carotid artery stent and predict 
suitability of surfaces for EC seeding.  ANSYS CFX modeling software will be used to 
calculate the shear stresses and oscillatory shear indices acting on adherent cells after 
implantation of the stent in a carotid artery, for both normal and hypertensive flow 
waveforms.  Both wall shear stress and oscillatory shear index are expected to have a 
significant impact on the phenotype and behavior of cells seeded to the surface.   We 
will compare the calculated shear stresses to our previous studies with ECs on titanium, 
to make predictions about the cells’ ability to remain adherent on the surface.    
 Specific Aim 2 Hypothesis:  Fluid stress conditions on the surfaces of an 
implanted carotid artery stent are amenable to supporting endothelial cell retention and 
antithrombotic function. 
 
Specific Aim 3:  Evaluate adhesion and function of seeded ECs on stents after 
deployment in vitro and in vivo.  In this study, stents will be seeded with blood-derived 
ECs minutes before deployment, either into an in vitro flow circuit, or in vivo in the 
carotid artery of pigs.  Stents will be seeded by infusion of a cell suspension into a 
modified stent delivery catheter, for both in vitro and in vivo portions of the study.  The 
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in vitro flow circuit will simulate shear stresses in vivo.  Retention and function of ECs on 
stent surfaces following physiological flow conditions will be evaluated after 24 hours.  
In the second part of the study, stents seeded with autologous porcine ECs will be 
deployed into porcine carotid arteries in vivo and evaluated after 48 hours of blood flow 
for cell presence and spreading as well as viability. 
 Specific Aim 3 Hypotheses:  (1) Modification of a commercial stent delivery 
system with micropores enables rapid infusion of ECs and adhesion to nitinol stents; (2) 
ECs remain adherent and spread to form a functional layer after stent deployment and 
under arterial fluid shear stress conditions. 
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2. Use of autologous blood-derived endothelial 
progenitor cells at point-of-care to protect against 
implant thrombosis in a large animal model 
The text and figures included in Chapter 2 were previously published in the 
November 2011 edition of Biomaterials.  The full citation for the article is:  Alexandra E. 
Jantzen, Whitney O. Lane, Shawn M. Gage, Ryan M. Jamiolkowski, Justin M. Haseltine, 
Lauren J. Galinat, Fu-Hsiung Lin, Jeffrey H. Lawson, George A. Truskey, Hardean E. 
Achneck.  Use of autologous blood-derived endothelial progenitor cells at point-of-care 
to protect against implant thrombosis in a large animal model.   Biomaterials, Volume 
32, Issue 33, November 2011, Pages 8356–8363.      
http://dx.doi.org/10.1016/j.biomaterials.2011.07.066.  Elsevier does not require 
permission for authors to reuse their own articles in a dissertation, but an optional 
license can be obtained and is included in Appendix B. 
2.1 Chapter synopsis 
This chapter describes the first phase of developing a point-of-care method for 
seeding titanium (Ti) vascular implants with autologous endothelium:  a materials proof 
of concept that endothelial cells will spread on Ti surfaces in vivo and prevent 
thrombosis in contact with the bloodstream.  Ti is commonly utilized in many 
cardiovascular devices, e.g. as a component of nitinol stents, intra- and extracorporeal 
mechanical circulatory assist devices, but is associated with the risk of thromboemboli 
formation.  We propose to solve this problem by lining the Ti blood-contacting surfaces 
 24 
with autologous peripheral blood-derived late outgrowth endothelial progenitor cells 
(EPCs) after having previously demonstrated that these EPCs adhere to and grow on Ti 
under physiological shear stresses and functionally adapt to their environment under 
flow conditions ex vivo.  Autologous fluorescently-labeled porcine EPCs were seeded at 
the point-of-care in the operating room onto Ti tubes for 30 min and implanted into the 
pro-thrombotic environment of the inferior vena cava of swine (n = 8).  After 3 days, Ti 
tubes were explanted, disassembled, and the blood-contacting surface was imaged.  A 
blinded analysis found all 4 cell-seeded implants to be free of clot, whereas 4 controls 
without EPCs were either entirely occluded or partially thrombosed.  Pre-labeled EPCs 
had spread and were present on all 4 cell-seeded implants while no endothelial cells 
were observed on control implants.  These results suggest that late outgrowth 
autologous EPCs represent a promising source of lining Ti implants to reduce 
thrombosis in vivo.  
2.2 Introduction  
Titanium (Ti) is commonly utilized as a component in the engineering of 
cardiovascular devices.  Examples include mechanical circulatory assist devices for the 
treatment of heart failure and nitinol vascular stents, which are coated with a layer of Ti 
on their blood-contacting surface and used in the treatment of peripheral vascular 
disease.  Whereas mechanical circulatory assist devices are associated with the risk of 
distal thromboemboli causing strokes[121], nitinol stents carry a high risk of in-stent 
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restenosis and thrombosis.  Approximately 40%-50% of bare metal nitinol stents in the 
femoropopliteal region are occluded within 2 years, and about 20% of patients who 
receive nitinol carotid artery stents will suffer from re-occluded stented neck vessels 
after only 2 years[122,123].  Further, nitinol stents occlude in >30% of patients with 
superficial femoral artery disease lesions after only 1 year[124].  Drug-eluting stents may 
provide for better outcomes.  However, no significant difference was found in a head-to 
head comparison between bare metal stents and sirolimus drug-eluting stents implanted 
into the infrainguinal vasculature[7].  Even in the coronary vasculature, drug-eluting 
stents that once held the promise of mitigating in-stent restenosis have been hampered 
by an increasing risk of late-stent thrombosis, likely due to incomplete coverage with 
healthy endothelium secondary to the drugs used[125].  We propose to solve these 
problems by lining the titanium blood-contacting surfaces of intravascular devices with 
autologous peripheral blood-derived endothelial progenitor cells (EPCs) within minutes 
of implantation.  Since these EPCs are derived from the same patient who would receive 
the cell-coated implant, there is no risk for rejection by the immune system.  The anti-
thrombotic endothelial coating would also reduce the necessity of anti-coagulative drugs 
for patients treated with intravascular devices, e.g. stents and circulatory assist devices, 
and reduce the bleeding complications associated with such medications.   
We have recently demonstrated that it is feasible to grow blood-derived EPCs on 
Ti surfaces, that EPCs grow to a confluent monolayer on Ti under static conditions and 
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physiological flow after only a few minutes prior adhesion time, and that EPCs adhere 
extremely well to such surfaces, even under supraphysiological shear stresses[126].  We 
have further shown that EPCs on smooth Ti surfaces functionally adapt to their 
environment under flow, produce nitric oxide (dependent on the magnitude of shear 
stress stimulation), and dramatically reduce platelet adhesion[126].  In order to provide 
the initial feasibility and benefit of such EPC-lined surfaces in a large animal model, we 
lined Ti tubes with porcine blood-derived EPCs and implanted these tubes into the 
inferior vena cava (IVC) of the pigs from which the cells were derived.  Uncoated ‘bare’ 
Ti tubes implanted under the exact same conditions served as controls.  We chose swine 
for this study because the pig is one of the most accepted animal models for studying 
coagulation biology, inflammation, and specifically vascular prostheses[127-130].  Since our 
null-hypothesis is that EPC-linings will not be able to reduce the incidence of 
thrombosis, we implanted the Ti tubes into the pro-thrombotic environment of the 
inferior vena cava, as opposed to the aorta, to increase the likelihood of thrombosis. 
2.3 Materials and methods 
2.3.1 Titanium tube assembly 
Ti tubes (commercially pure, grade 2) were purchased with dimensions 12.7mm 
ODand 9.4mm ID (TicoTitanium) and cut to a length of 45 mm.  Tubes were sectioned 
into 3 equal segments longitudinally with a high speed steel saw.  The inner surfaces 
were polished with a bench grinder and metalworking wheel (Scotch-Brite), followed by 
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manual polishing with emery cloth (3 M) to further even out the surface and remove any 
visible pits.  Ti sections were then cleaned with Alconox soap solution and aqua regia 
(1:3 concentrated nitric acid to concentrated hydrochloric acid) as previously described 
for Ti surfaces[131].  Sets of three Ti sections were reassembled into tubes with Polyvinyl 
chloride (PVC) heat shrink tubing (Insultab, expanded ID 15.88 mm, recovered ID 7.95 
mm).  For the assembly of our seeding chamber, silicone tubing (16.64 mm OD, 9.52 mm 
ID, 3 cm length) was added to both ends of the Ti tube and a ‘cut-off’ syringe head with 
luer was added to one end (Figure 2.1).  All components were gas sterilized prior to use 
(18 h, 55 °C). 
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Figure 2.1: Ti tube seeding and implantation.   
(A)Ti tube seeding device and Ti tube seeding chamber.  The Ti tube is placed inside 
the aluminum holder. To assemble the seeding chamber, a ‘cut-off’ syringe head with 
luer is attached via silicone tubing to the Ti tube (left end of Ti tube) and a 5 cc 
syringe is attached via silicone tubing (right end of Ti tube).  The level gauge ensures 
equal distribution of EPCs during rotation of the seeding chamber.  A sterile sheath 
surrounding the seeding chamber has been removed in order to facilitate viewing of 
the seeding chamber inside the aluminum holder.  (B) Intraoperative view of 
skeletonized infrarenal IVC, prior to venotomy. The proximal end of the IVC is 
encircled with a yellow vessel loop (left).  The overlying right renal artery is encircled 
with a blue vessel loop (left).  A blue vessel loop encircles the left 7th lumbar vein.  
The distal IVC is encircled with a yellow vessel loop at its bifurcation into the 
common iliac veins (right) and the right external iliac artery is encircled with an 
orange vessel loop as it crosses the right common iliac vein (far right).  (C) Ti tube 
insertion into IVC.  Both ends of the IVC are clamped.  The blue PVC heat shrink 
tubing is recognizable inside the IVC.  (D) Post-insertion view of the infrarenal IVC.  
The yellow vessel loop encircles the proximal IVC.  Note the 6-0 polypropylene ‘stay 
suture’ that was placed through the adventitia and PVC heat shrink tubing to prevent 
the device from migrating (white arrow).  
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2.3.2 X-ray photoelectron spectroscopy 
The atomic composition of our Ti samples was determined using a Kratos Axis 
Ultra X-ray Photoelectron Spectroscope and compared to the surface of a Cordis Precise 
RX self-expanding Nitinol stent.  Spectra were obtained at 2.0 x 10-8 Torr using a 
monochromated aluminum K-alpha X-ray source at a power of 15 kV and an emission 
current of 10 mA.  Survey scans were performed over the range of 5-1200 eV with a step 
eV of 1, a dwell time of 200 ms, a resolution of 160 eV, and a slot aperture measuring an 
area of 300 μm x 700 μm.  A regional scan for titanium was performed on both samples 
over the range of 450-470 eV with a step eV of 0.1, a dwell time of 298.5 ms, a resolution 
of 160 eV, and the same slot aperture.  In addition, a survey scan of the stent was 
performed using a “small spot” field of view with a 2 mm aperture measuring a 110 μm 
diameter spot on the stent surface and the same scanning parameters used for the 
previous survey scans.  The elemental peaks of the samples were ascertained from 
survey scans using CasaXPS software and utilizing a relative sensitivity function library 
specific to the Kratos Axis Ultra system. 
2.3.3 Optical profilometry 
Surface roughness was analyzed by optical profilometry (Zygo NewView 5000).  
The 3D surface profiler uses non-contacting white light interferometry to acquire high 
resolution z-images, from which surface roughness averages (Ra) are reported according 
to equation (1) [132], after subtraction of a “cylinder” shape in the system software 
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(MetroPro, Zygo) to account for and remove the curvature of the tube itself. 
    
 
 
     
 
   
 
 where yi represents the differences between the surface profile and the surface mean 
line for the ith data point of n equally spaced data points along a trace.  Three fields (0.72 
x 0.5 mm each) were measured on each of 3 Ti tube sections, and all Ra values from a 
single Ti tube section were averaged to obtain n = 1 for a total sample size of n = 3. 
2.3.4 EPC isolation 
All experiments with swine were approved by the Duke University Institutional 
Animal Care and Use Committee (IACUC) and were conducted in accordance with the 
National Institute of Health Guidelines for the Care and Use of Laboratory Animals.  
Yorkshire swine (2 male, 6 female, at an initial weight of 46.6 ± 0.89 kg) underwent a 
blood draw 30 days prior to Ti tube implantation to allow sufficient time for EPC 
isolation and amplification in culture (only 4 pigs actually received cell-seeded implants, 
the other 4 received bare metal control implants).  The pigs were sedated with 
Acepromazine (1.1 mg/kg) and Ketamine (22 mg/kg) intramuscular.  Intubation was 
achieved with an endotracheal tube (30 cm length, 8 mm ID), and the pigs were 
anesthetized with Isofluorane by mask.  The pigs’ groins were cleaned and sterilized 
with DuraPrep, and femoral vein access was obtained with a 5 F micro-introducer kit 
(Galt Medical) using the Seldinger technique[133].  After discarding the first 5 mL of 
blood, 45 mL of blood were collected into syringes containing 10 mL anticoagulant 
(1) 
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citrate dextrose solution (Pall Corporation).  This was followed by 1:1 dilution with 
Hank’s buffered salt solution (without CaCl2, MgCl2, MgSO4) and layered on equal 
volumes of Histopaque to create well-defined layers.  The mononuclear cell layer was 
collected as described previously[126] and plated into two 12-well plates in full EPC 
growth medium (MCDB-131 medium with 2 mM Lglutamine, Cellgro, 2% porcine 
serum, Gemini Bio-Products, and EGM-2 SingleQuots,Lonza) at 37 °C, 5% CO2. 
2.3.5 Flow cytometry 
For each cell isolation, EPCs were tested with flow cytometry for presence or 
absence of surface markers CD31 (Platelet Endothelial Cell Adhesion Molecule 1, 
PECAM-1), CD14 and CD45, as described for these cells previously[126].  Further, we 
tested for CD 106 (Vascular Cell Adhesion Molecule 1, VCAM-1) with directly 
fluorescein isothiocyanate-conjugated mouse anti-porcine VCAM-1 antibody (Antigenix 
America, APG106F).  Mouse IgG1 served as isotype control. 
2.3.6 Titanium tube seeding 
The custom device for seeding Ti tubes was built by mounting a synchronous 
timing motor (Herbach & Rademan) on a plexiglass machined stand that has adjustable 
legs to allow adjustment of rotating device with a water leveling gauge (Swanson).  The 
motor was connected via a stainless steel axle to a machined aluminum holder with a 
mold fitting the Ti tube seeding chamber of Section 2.3.1. (Figure 2.1A).  For in vitro 
seeding experiments, adherent EPCs were labeled with the fluorescent dye Cell Tracker 
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Orange CMRA (Invitrogen) in serum-free medium (15 min, 37 °C).  For in vivo 
experiments, adherent EPCs were labeled with the long-term fluorescent dye PKH26 
(Sigma-Aldrich) at a concentration of 4 μM (4 min, room temperature), and the reaction 
was stopped with porcine serum (Gemini Bio-Products).  Following labeling, cells were 
dissociated with Trypsin (0.25%, Lonza, at 37 °C for 3 min) and counted, then re-
suspended to a final concentration of 2.0 x 106 cells/mL (see Section 2.4.5. for 
optimization of cell suspension density) in serum-free medium EBM-2 (Lonza) with 
EGM-2 SingleQuots (Lonza).  The EPC suspension was introduced into the Ti tube by a 
syringe attached with silicone tubing (Figure 2.1A), and a luer cap added to the end of 
the ‘cut-off’ syringe head after purging all air bubbles from the Ti tube.  The Ti tube was 
placed inside a sterile sheath to maintain sterility of the system and secured into the 
machined aluminum holder (Figure 2.1A).  Next, the seeding device with cell 
suspension was rotated for 30 min at 37 °C in ambient air at 10 rotations per hour, as 
determined empirically in preliminary studies.  To evaluate adherent EPCs after the 
seeding period, Ti tube sections were rinsed twice in phosphate-buffered saline (with 
CaCl2 and MgCl2, PBS) after seeding and fixed in 10% formalin for 15 min, followed by 2 
more rinses with PBS.  Cell areas were measured in 100-120 cells per Ti tube section 
using Image J software immediately after 30 min seeding by rotation (designated time 
zero) and after a 24 h static culture time following the seeding by rotation period 
(designated as time 24 h).  Values within each Ti tube section were averaged for a single 
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sample; data from four samples were obtained at time zero and data from three samples 
after 24 h static culture.  To evaluate the surface density of adherent cells after the 
seeding period, the total number of cells was determined in 20 random fields per Ti tube 
section (Image J).  Cell numbers were divided by the area of each field to obtain a 
density.  Values from all fields within each experiment were averaged to obtain each n = 
1, and a total of n = 3 Ti tubes were used at each of three different EPC suspension 
concentrations.  The overall percent of cells adherent after seeding was calculated using 
the cell suspension concentration, volume and surface area for each Ti tube. 
2.3.7 Shear stress approximation in porcine inferior vena cava 
Vessel dimensions and flow rates were measured in an exploratory surgery in a 
pig (50 kg, representative of the size of pigs at device implantation) with an ultrasonic 
perivascular flow probe (Transonic), allowing the wall shear stress τ (dyn/cm2) to be 
estimated according to[134] 
   
   
   
 
where, μ is the blood viscosity at 37 °C (0.0465 g cm-1 s-1)[135], Q is the measured 
volumetric flow rate (8.33 cm3/s), and r is the measured vessel radius (0.7 cm).  Therefore 
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Since this shear stress is approximately ten-fold lower than the 15 dyn/cm2 commonly 
used to model arterial flow[134], the IVC provides a pro-thrombotic environment in which 
to challenge our EPC-seeded devices. 
2.3.8 Ti tube implantation in swine 
Eight Yorkshire swine (2 male, 6 female, at a weight of 52 ± 1.6 kg) underwent 
consecutive surgeries with either EPC-seeded or bare metal device implantations (see 
Jantzen et al. Supplementary Data, Swine preparation for surgery and Swine 
laparotomy[136]).  After the IVC had been identified we used sharp and blunt dissection 
to free the vessel from the surrounding tissue and skeletonize it circumferentially from 
the level of the right renal vein proximally to its iliac bifurcation distally (Figure 2.1B).  
Several lumbar veins were ligated with silk sutures and divided to prevent any 
retrograde bleeding around the implanted Ti tube once venous circulation was restored.  
Before proceeding any further, the Ti tube seeding was initiated in the operating room 
with fluorescently-labeled EPCs with our seeding device as described in Section 2.3.6.  
Unseeded bare metal Ti tubes were implanted as controls. 
100 USP/kg of heparin was administered intravenously 5 min prior to clamping 
the IVC (and completion of the seeding process).  A profunda clamp was placed, first on 
the distal end of the IVC at the iliac bifurcation, then proximally just distal to the right 
renal vein using a 45° straight vascular clamp.  A # 11 scalpel blade was used to create a 
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small venotomy in the middle of the exposed segment.  This was extended with Potts 
scissors to fashion a longitudinal venotomy measuring 4 cm in length (Figure 2.1C). 
The Ti tube was implanted (see Jantzen et al. Supplementary Data, Ti tube 
insertion[136]) and two 2-O silk ties were placed around the IVC containing the device (at 
the proximal and distal end of the Ti tube) to prevent the development of a false lumen 
(Figure 2.1D).  Moreover, one 6-O polypropylene ‘stay suture’ was placed through the 
IVC’s adventitia into and through the heat shrink PVC tubing to prevent migration of 
the device inside the IVC (Figure 2.1D).  The abdomen was then closed and the pig 
recovered (see Jantzen et al. Supplementary Data, Swine abdominal closure[136]).  All 
surgeries were accomplished without any unforeseen complications.  The blood loss was 
minimal in all procedures.  The duration of IVC clamp time was similar between the 
groups (Figure 2.2A).  Furthermore, there was no significant difference in the total 
anesthesia time or the time pigs were immobilized for surgery between the cell-seeded 
treatment group and control group (Figure 2.2B).  All eight pigs in the study mobilized 
and fully recovered before device explantation 3 days later. 
  
 36 
 
Figure 2.2: Intraoperative clamp times of IVC during insertion and total time of 
anesthesia during surgery (in hours). 
(A) Intraoperative clamp times of IVC during device insertion. Clamp times were not 
significantly different between EPC-seeded and control implant groups (15.5 ± 2.3 
min and 13.8 ± 1.2 min, respectively, p = 0.517, n = 4 for each group, two-tailed t-test).  
(B) Total time of anesthesia during surgery (in hours). Duration of anesthesia was not 
significantly different between EPC-seeded and control implant groups (6 h 19 min ± 
31 min vs. 5 h 7 min ± 41 min, p = 0.21, n = 4 for each group, two-tailed t-test). 
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2.3.9 Ti tube explantation 
Three days after implantation, pigs were sedated, intubated and anesthetized as 
described above.  The laparotomy and dissection were conducted as outlined previously 
and the Ti tube was explanted en bloc after clamping the IVC proximal and distal and 
transecting the IVC proximal and distal with heavy scissors.  The pig was euthanized 
after the device had been explanted with Euthasol euthanasia solution (390 mg/mL 
Pentobarbital Sodium and 50 mg/mL Phenytoin Sodium at 1 mL/10 lbs) according to our 
IACUC protocol.  The Ti tube was immediately rinsed with PBS x 3 and its lumen 
photographed from both ends with a high resolution digital camera (Nex-3, Sony).  The 
implant with clot (if present) was then submerged in 3.7% paraformaldehyde for 
fixation for 4 h.  After fixation, the Ti tube was opened by incising the PVC heat shrink 
tubing with a # 15 scalpel blade and its inner surface photographed as well.  None of the 
pigs received any form of anticoagulation other than the initial heparin bolus 5 min 
prior to implantation of the device (treatment and control alike). 
2.3.10 Thrombosis scoring 
Thrombosis outcomes of explanted Ti tubes were classified into three categories: 
‘Fully clotted,’ ‘partially clotted,’ or ‘no clot.’  Clots in the ‘fully clotted’ category 
extended throughout the entire length and cross-section of the tube lumen, whereas 
‘partial clots’ did not fill the tube, either in length or in cross-section.  Tubes, which were 
clean with no significant thrombosis, were classified as ‘no clot.’  Outcomes were scored 
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by presenting the gross photographs of the device lumina and their opened sections to 
three separate reviewers, who were blinded as to whether the device had been seeded 
with EPCs or was a control implant.  Where the reviewers disagreed in their 
classification, we biased their assessment towards the null-hypothesis, that there is no 
difference in outcome between cell-seeded and bare Ti tubes, e.g. if a bare metal tube 
were rated ‘partially clotted’ vs. ‘fully clotted,’ we would classify it as ‘partially clotted.’ 
2.3.11 Immunohistochemistry/microscopy 
In addition to the pre-implantation label PKH26 (Sigma-Aldrich), cell nuclei of 
fixed Ti tube segments were stained with Hoechst 34580 nucleic acid stain (Invitrogen, 
diluted 1:1000 in PBS x 15 min).  To stain Ti tube sections for PECAM-1 (cell-cell 
junctions), samples were incubated with mouse anti-porcine CD31 (Antigenix America 
#APG311, diluted 1:100, for 1 h at 37 °C) after blocking with 10% normal goat serum 
(Gibco, for 30 min at RT).  Samples were then rinsed x 3 with PBS and incubated with 
the secondary antibody goat anti-mouse AlexaFluor488 (Invitrogen #A-11001, diluted 
1:500, for 45 min at 37 °C).  Appropriate positive and negative control experiments were 
performed to rule out non-specific antibody binding to Ti surfaces.  Following 3 more 
washes with PBS, samples were visualized with an upright Leica DMRB fluorescent 
microscope with a Qimaging Qicam monochrome digital camera and Image Pro Plus 
software (Leica).  Cell surface area was determined with Image J software, after seeding 
x 30 min vs. subsequent in vivo experiments x 3 days, as described in Section 2.3.6.  The 
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confluent density was calculated by counting the number of cells per field as described 
in 2.3.6.  Additionally, samples were imaged with a Zeiss 780 confocal upright fixed 
stage microscope and 10x objective (Zeiss), and images were captured with Zeiss 
software. 
2.3.12 Statistics 
To evaluate cell spreading, a one-way ANOVA was performed comparing the 
area of cells at time point zero after seeding, after 1 day of static culture, and after 3 days 
in vivo (on the Ti tube implanted surface), followed by a post hoc two-tailed t-test.  A 
one-way ANOVA was also used to test for differences in cell adhesion percentage with 
cell suspension density.  Assuming a linear relationship between adhesion density and 
cell suspension[137,138], correlation of these variables was performed with a linear 
regression analysis, followed by an F-test to confirm that the slope was significantly 
different from zero.  A two-tailed t-test was used to compare IVC clamp time between 
treatment and control groups and total time of anesthesia between both groups, 
respectively.  To compare thrombosis between control and cell-treated implants after 3 
days in vivo, a 2 x 3 contingency table was used with the Fisher’s exact test[139].  The 
significance level was assumed to be 0.05 for all tests.  Results were reported as mean ± 
standard error. 
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2.4 Results 
2.4.1 Ti surface composition 
X-ray photoelectron spectroscopy indicated that the chemical composition of the 
nitinol self-expanding stent (Cordis) was very similar to our manufactured Ti tube 
surfaces.  Regional scans of Ti 2p ranges showed that both our Ti tube and nitinol stent 
were composed of Ti primarily as TiO2, with Ti 2p3/2 peaks matching an expected peak at 
458.8 eV[140] (Figure 2.3A,B).  Of particular interest, XPS revealed the absence of nickel on 
the stent surface in the survey scan, confirming that polishing of the nitinol stents by the 
manufacturer results in a titanium oxide outer layer on the alloy surface. 
  
 41 
 
Figure 2.3:  XPS spectrum of Ti tube and nitinol stent. 
(A) XPS spectrum of Ti tube with binding energy peaking at 458.9 eV, corresponding 
to the Ti 2p3/2 electron configuration. (B) XPS spectrum of the nitinol stent with 
binding energy peaking at 459.1 eV, indicating comparable TiO2 composition. Note 
that the nitinol stent was imaged in its expanded state with a small field of view 
focusing on a stent strut only, whereas the titanium tube was imaged with a larger 
field of view, which is reflected by the difference in signal intensity (measured in 
counts per second) between the Ti tube and nitinol stent. 
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2.4.2 Ti surface topography 
The surface topography of our Ti tubes was evaluated with optical profilometry.  
The roughness average (Ra) for the titanium tubes was found to be in the sub-
micrometer range (0.59 ± 0.02 μm, n = 3), similar to roughness values reported for nitinol 
alloys used in biomedical applications [141]. 
2.4.3 Flow cytometry results 
All EPCs exhibited typical cobblestone morphology by phase contrast 
microscopy and tested positive for presence of PECAM-1 and negative for surface 
markers CD14 and CD45.  Further, we confirmed absence of VCAM-1 for cells cultured 
in vitro, which, if present, would indicate an undesirable pro-inflammatory activated 
phenotype of our endothelial progenitor cells [142,143]. 
2.4.4 EPC adherence and spreading on Ti tube surface ex vivo 
EPCs seeded onto Ti tubes with our seeding device (Figure 2.1A) and cultured 
under static conditions for 24 h adhered to and spread on the Ti surface and formed a 
confluent layer.  Cell areas were significantly greater after 24 h of static culture than 
immediately following cell seeding (852.0 ± 23.2 mm2 vs. 184.5 ± 6.1 mm2, p < 0.0001, 
Figure 2.4A).  We found in these seeding experiments with static culture that seeding 
concentrations of 1-2 x 106 cells/mL resulted in confluent cell coverage after 24 h. 
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Figure 2.4:  EPC Spreading on Ti tubes and EPC surface coverage with 
suspension density. 
(A) EPC Spreading on Ti tubes at time zero after seeding, after 1 day of static culture 
ex vivo, and after three days in vivo. EPCs’ area was significantly greater at 1 and 3 
days than at time zero (p < 0.0001, n = 3 at 1 day, n = 4 at 0 and 3 days, 1-way ANOVA 
and post hoc t-test).  (B) EPC surface coverage with suspension density.  The number 
of adherent cells per area significantly increased as suspension concentration 
increased (p < 0.001, r2 = 0.82, n = 3 for each concentration, linear regression analysis).  
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2.4.5 EPC suspension density 
The number of adherent cells inside the Ti tubes immediately after the 30 min 
seeding process increases with the cell suspension concentration (Figure 2.4B).  To 
compensate for any possible loss of EPCs during handling in the surgical implantation, 
we determined the optimal seeding density of 2 x 106 cells/mL.  This resulted in a greater 
number of cells adhering to the surface than required for a confluent layer of EPCs 
inside the Ti tubes (1.41 ± 0.11 x 105 cells/cm2 adherent vs.1.04 ± 0.03 x 105 cells/cm2 at 
confluence after 24 h of static culture, n = 3 for each concentration tested).  The optimal 
suspension density was used for all in vivo experiments.  Only 34% ± 9% (n = 9) of the 
total number of cells in suspension adhered, and the percentage of adherent cells was 
not significantly different for different suspension densities (p = 0.27).  
2.4.6 Thrombosis results 
Thrombosis results, as scored by blinded reviewers, are as follows: In the bare 
metal control group, 2 of 4 implants were fully clotted (Figure 2.5A,B) and 2 of 4 
implants were partially clotted (Figure 2.5C,D).  All EPC-seeded Ti tubes (4 of 4) were 
free of clot after 3 days implantation (Figure 2.5E,F). By Fisher’s exact test[139], the 
treatment significantly protected against thrombosis (p < 0.03). 
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Figure 2.5:  Categorization of thrombosis outcomes. 
Representative pictures of Ti tubes (A,B) fully clotted, (C,D) partially clotted, and (E, 
F) not clotted. Tubes are shown in two orientations -a transverse view with tubes 
intact (left column)- and in a longitudinal view of the inner surface after tube 
dissection (right column). 
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2.4.7 EPC retention and spreading inside Ti tubes in vivo 
The autologous fluorescent EPCs, which were seeded onto Ti tubes before 
surgery, were visualized on every one of the 4 cell-seeded implants after 3 days in vivo 
and found to have spread on the surface to form a confluent monolayer (Figure 2.6A,B).  
The area per cell was significantly greater after 3 days exposed to blood flow than 
immediately following cell seeding (842.5 ± 16.0 μm2 vs. 184.5 ± 6.1 μm2, p < 0.0001), but 
not significantly different than the area of confluent cells cultured under static 
conditions ex vivo (842.5 ± 16.0 μm2 vs. 852.0 ± 23.2 μm2, p = 0.74, Figure 2.4A).  All 
endothelial cells visualized on the EPC-seeded Ti tubes contained PKH26 (red), 
suggesting that they were of pre-seeded EPC origin.  Immunohistochemical 
counterstaining of the pre-labeled fluorescent EPCs on the explanted Ti device surface 
with anti-PECAM-1 antibodies confirmed that all endothelial-like cells on the Ti surface 
had maintained their endothelial-like-morphology in vivo (Figure 2.6A,B).  Since there 
were no endothelial cells observed on the surface that did not exhibit the pre-
implantation florescent EPC label, we conclude that no ‘fall-out’ endothelial cells from 
blood had adhered to and populated the implant surface.  Anti-PECAM-1 staining of 
thrombus-free areas in the partially occluded Ti tubes failed to reveal any endothelial 
cells.  However, we did find clusters of leukocytes (based on nuclear morphology) in 
those areas of bare metal implants (Figure 2.6C). 
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Figure 2.6:  Cells on Ti surface following 3 days in vivo implantation. 
EPCs on Ti surface were stained for PECAM-1 (green) after 3 days in porcine IVC. (A) 
Scale bar = 200 μm (B) EPCs additionally showing pre-implantation stain PKH26 (red) 
and nuclei stained with Hoechst 34580 (blue). Scale bar = 50 μm. (C) Cell nuclei on 
bare metal control implant surface stained with Hoechst 34580, showing presence of 
macrophages, T cells and granulocytes in a non-uniform distribution. Scale bar = 100 
μm. 
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2.5 Discussion 
Our results demonstrate that blood-derived EPCs can protect against thrombosis 
in a short-term large animal model.  We chose to use pigs as the animal model for this 
study because their anatomy and physiology closely resembles that of humans[144].  
Additionally, the vessel size of our 50 kg pigs is very similar to those of children or small 
adults.  
Since our ex vivo studies had previously demonstrated that late outgrowth EPCs 
on Ti surfaces can withstand more than 5-10-fold higher shear stresses than they would 
encounter in the arterial circulation [126], we elected to evaluate the EPCs’ functional 
benefit in the low shear stress environment of the inferior vena cava, which biases our 
outcomes towards thrombosis, rather than implanting them into the higher shear stress 
environment of the aorta.  Furthermore, porcine blood is hypercoagulable as compared 
to human blood[127].  Still, EPC treatment was able to prevent clot formation in all 4 of 4 
implants. Moreover, in our earlier studies we had shown that EPC treatment blocks 
platelet adhesion to the titanium surface [126].  Therefore, we believe that EPC treatment 
will even more so prevent thrombosis in humans, especially when utilized to line 
intravascular devices in the higher shear stress environment of the arterial system.  In 
order to prevent the introduction of bias in evaluating our surgical outcomes -- device 
thrombosis or patency -- we had 3 different investigators, who were blinded to the 
treatment of Ti tubes, and had them score the degree of thrombosis in high resolution 
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photographs of the implants.  Whereas everyone had judged the cell-treated devices to 
be free of clot, there was some disagreement among investigators in 2 control implants 
as to whether they should be classified as fully thrombosed or partially thrombosed. 
According to our scoring system, these were automatically biased towards the null-
hypothesis of no difference between the groups and ranked as only partially 
thrombosed.  Still, we were able to find a statistically significant difference in the 
outcomes of our 8 consecutive surgeries with p < 0.03. 
It is well established that the duration of surgery and anesthesia time is 
associated with the risk for venous thrombosis [145-147].  Therefore, we compared the total 
time each pig was immobilized for the procedure (total time of anesthesia) between the 
groups.  We did not find any significant difference - in fact, the anesthesia time was 
slightly longer in the EPC-treated device implantations as compared to that of bare 
metal devices.  Furthermore, the cross clamp time is directly related to venous 
thromboembolism[148].  Therefore we compared the average clamp times between 
treatment group and control group and also failed to find a significant difference. 
Since all technical aspects of the surgeries were identical and bias was avoided in 
the scoring of surgical outcomes, we conclude that our results are a real representation 
of the protective effect of autologous blood-derived EPCs in our large animal model.  
We believe that this conclusion is confirmed by the presence of our fluorescently pre-
labeled EPCs in all 4 implants after 3 days in vivo.  However, cells other than EPCs were 
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also observed on some of the Ti blood-contacting surfaces.  These cells were present 
overlying confluent areas of EPCs (as confirmed by PKH26 and PECAM-1 stains, see 
Jantzen et al. Figure S2 A,B)[136].  Based on the cells’ nuclear morphology, they appeared 
to be cells of the innate immune system.  The distribution of these leukocytes was non-
uniform with some fields of view revealing large aggregations while others showed very 
few, if any at all.  We hypothesize that the presence of leukocytes relates to either the 
low shear environment “activating‟ EPCs, or to the short-term nature of the study and 
the fact that Ti tubes were explanted 3 days after the initial surgical insult.  Testing of 
these hypotheses will be possible in future longer-term implantation studies. 
One other limitation of our study is the observation that we did not find 100% of 
the Ti blood-contacting surface area covered with EPCs.  We contribute this to the cells 
“peeling off‟ as a sheet during the disassembly process of the Ti tube.  In fact, we did see 
distinctive “peel line‟ demarcations when examining our implants (See Jantzen et al., 
Figure S3[136]).  Since the implants had been fixed in paraformaldehyde prior to 
disassembly, we hypothesize that cells are more strongly linked to each other than they 
are to the underlying Ti surface – and invariably separate from the undersurface when 
the Ti tube sections are broken apart.  In future evaluations of currently ongoing long-
term implantations, we may be able to prevent this problem by either utilizing an 
endoscope to examine the device lumen without taking it apart after explantation, or a 
Cellvizio LAB imaging system (Visualsonics) that allows for insertion of a small 
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diameter fiberoptic microprobe percutaneously into the IVC and device lumen to image 
the inside surface in live animals.  We have already successfully conducted an 
exploratory trial with the minimally invasive Cellvizio system in 2 long-term 
implantations in vivo to ascertain presence of pre-labeled EPCs in patent implants (3 
weeks, see Jantzen et al. Figure S4 A,B[136]). 
Our X-ray photoelectron spectroscopy spectra and optical profilometry results 
show that our Ti tubes are similar to titanium-coated biomedical implants in atomic 
composition and surface roughness.  Studies are currently underway to adapt our 
technology of point-of-care seeding to self-expanding Ti-coated nitinol stents.  The same 
principles, however, can be used to coat many other implantable devices, e.g. the inflow 
cannula of ventricular assist devices in an effort to engineer an anti-thrombotic universal 
inflow conduit for mechanical circulatory support systems. 
Since EPCs used in this proof-of-concept study are derived from peripheral 
blood, invasive methods of harvesting endothelial cells are avoided.  Especially in sick 
patients who are most likely to benefit from implantation of cell-coated devices, an 
additional surgery to harvest cells could be avoided.  Unlike other types of stem cells, 
e.g. induced pluripotent stem cells[149], our autologous EPCs have the important 
advantage of not requiring immunosuppression of the recipient patient.  This not only 
avoids the significant side effects of immunosuppressive drugs but also their propensity 
to expose patients to opportunistic infections. 
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Finally, our technology avoids impractical ex vivo culture times of EPCs on the 
device surface.  Whereas cell-seeding approaches have been hindered by the 
requirement to culture cells together with the device before implantation into a patient, 
we now have successfully demonstrated that blood-derived EPCs will spread on the 
three-dimensional Ti-blood-contacting surface after only a short seeding time with our 
rotating seeding device at the point-of-care and form a confluent cell layer in vivo.  
Longer-term implantation studies are currently underway with the goal of translating 
this cell-seeding technology into clinical practice.  
2.6 Conclusions 
We have demonstrated the feasibility to utilize autologous blood-derived 
endothelial progenitor cells to seed the blood-contacting surface of vascular devices at 
the point-of-care.  Further we have provided first proof-of-concept in a large animal 
model that such EPC-coatings of titanium surfaces protect against device thrombosis.  
This technology can be used to protect Ti blood-contacting surfaces, e.g. nitinol vascular 
stents, mechanical circulatory assist devices, and blood-contacting extracorporeal 
devices against the devastating complications of device thrombosis and thromboemboli 
formation.  Longer-term implantation studies are needed to pave the way for translating 
this technology into clinical practice. 
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3. Calculated shear stresses in implanted carotid stent 
surfaces are conducive to endothelial cell seeding 
and retention 
Portions of the text and figures included in Chapter 3 have been submitted to the 
Journal of Biomechanics for publication.  This article does not yet have a publication 
date; the Journal of Biomechanics does not require permission for authors to reuse their 
own articles, but an optional grant of license may be obtained as soon as one is available, 
through Rightslink®.   
3.1 Chapter synopsis 
Implantation of a vascular stent into a blood vessel is known to change flow 
patterns and the distribution of local wall shear stress (WSS).  Point-of-care seeding of 
nitinol stents with endothelial cells can potentially reduce long-term complications such 
as intimal hyperplasia and thrombosis and improve vascular function.  Implantation of a 
vascular stent into a blood vessel changes flow patterns and the distribution of local wall 
shear stress (WSS).  We applied computational fluid dynamics methods to test the 
hypothesis that WSS and oscillatory shear index (OSI) on various surfaces of a 
commercial vascular stent are within a range that could support retention of rapidly 
seeded endothelial cells.  We computed WSS and OSI on the stent under conditions 
representing hypertension and reduced vessel compliance.  Time-averaged shear 
stresses were highest on lumenal stent surfaces in both normal and hypertensive flow 
conditions, and lower on lateral struts.  Time-averaged shear stresses changed 
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minimally between normal and hypertensive models.  Over the cardiac cycle, time-
averaged shear stresses were <5 Pa (<50 dyn/cm2) on all stent surfaces.  Peak transient 
shear stresses were <27.5 Pa (<275 dyn/cm2) on all stent surfaces, and highest on the 
lumenal surface.  OSI was highest on stent lateral surfaces and lower on lumenal 
surfaces.  Local flow reversal occurred at the vessel wall for a portion of the cardiac 
cycles.  OSI was lower in the hypertensive flow model on all studied surfaces, 
corresponding to reduced vessel compliance and reduced fluctuation of the input 
waveform.  The magnitude and temporal profile of shear stress and OSI on an 
implanted stent surface should enable endothelial cell retention and antithrombotic 
function, although regions that exhibit flow reversal may alter endothelial cell function. 
3.2 Introduction 
 
Vascular stents are commonly used to restore blood flow in a restricted coronary 
or peripheral artery lumen.  Despite the general success of these stenting procedures, 
restenosis after thrombosis or intimal hyperplasia is a persistent problem in a substantial 
number of patients[7,33].  Covering the blood-contacting surfaces of stents with a layer of 
functional endothelium is an attractive strategy investigated by our group and others to 
reduce thrombogenicity of the material[63-65,67,68,74,136].  Shear stresses on the stent members 
under typical physiological conditions are of particular interest for potential 
endothelialization of the stent device; we have previously shown that endothelial cells 
(ECs) can be retained and maintain positive antithrombotic function on Ti surfaces 
 56 
under sustained shear stresses of 100 dyn/cm2, so time-averaged shear stresses at or 
below this level are preferred for surfaces to be seeded with endothelium. 
Computational modeling of stents has been used to examine deployment forces 
within the stent material[99], elution profiles of drug coated stents[100], and fluid shear 
stresses on vessel endothelium within a fully deployed stent[101-104].  These studies 
examine how a stent placed in an artery disturbs local flow patterns and imparts stress 
to the artery wall.  In a three-dimensional flow model including recirculation through a 
drug-coated stent in a coronary artery[100], drug distribution was affected by stent 
geometry and flow, and transient accumulation of drug occurred in the vessel 
downstream of the stent.  While some of the previous work examines shear stress on the 
stented vessel wall, shear stresses on the stent itself have not previously been reported.  
Decreasing the thickness of struts (thickness measured in the radial rather than 
circumferential direction) could significantly reduce the areas of low wall shear stress 
downstream of each strut[150].  Other computational studies also showed that struts of 
reduced thickness, more aligned with the primary flow direction, decrease the effect of 
low wall shear stress on the arterial wall[109,110].  In contrast, reducing the width of 
modeled stent struts increased the vessel area exposed to low wall shear stress (defined 
as <0.5 Pa)[109].  In a slightly different application of stent modeling, computation has also 
been used to predict areas of likely EC denudation following expansion of a balloon-
expandable stent[151].   
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Low wall shear stress, known to correlate with atherosclerosis, also frequently 
occurs between stent struts and correlates with hyperplasia leading to stent restenosis[111-
113].  Low shear stress also corresponds to areas of inhibited EC migration onto stents[114].  
Stent strut spacing has a strong effect on wall shear stress, flow stagnation and 
recirculation[102,103,115].  Although vascular stents alter blood flow patterns close to the 
stent structure, most previous work has focused on the adjacent vessel wall and not on 
shear stresses experienced by the stent struts themselves.  Additionally, most previous 
work has focused on only healthy human waveforms and not models of vascular disease 
or hypertension, as we do here.  While some studies have examined peripheral vascular 
stents, a majority of modeling has focused on coronary stents, subject to very different 
hemodynamics and shear stresses. 
After only a 15-minute period of attachment approximately 90% of endothelial 
progenitor cells (EPCs) are retained on titanium surfaces, even at shear stresses of 30 
Pa[126].  We also found that cells spread on a Ti surface remain adherent and express 
nitric oxide (NO) and antithrombotic genes when subjected to 10 Pa shear stress.  We 
have used computational fluid dynamics modeling to assess shear stresses on the 
titanium housing of a left ventricular assist device, finding that all surfaces but the outlet 
tube experienced shear stresses above 10 Pa, and were likely not suitable for 
endothelialization[120].  Nitinol stents are covered with a layer of titanium oxide on the 
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outer surface, and so we are extending our work with Ti and endothelial cells to nitinol 
stents. 
Our long-term goal is to endothelialize nitinol stents immediately prior to 
deployment, without extensive culturing of the stent and cells together.  As such, the 
shear stresses experienced by cells on various parts of the stent geometry are of special 
interest to us as they relate to initial cell retention as well as longer-term viability of a 
seeded endothelial layer.   
Our objectives in this study were to calculate shear stresses on the stent surface 
and the degree of reversing flow; these two parameters are expected to have a 
significant impact on the phenotype and behavior of cells seeded to the surface.  Because 
patients receiving stents may be expected to have a degree of hypertension, 
atherosclerosis, and/or vessel stiffening, we modeled both a normal baseline carotid flow 
waveform, and a carotid flow waveform representing moderate hypertension with 
reduced vessel compliance, representing blood pressures in excess of 160/90 mmHg[152].  
We compare the calculated shear stresses to our previous studies with ECs on titanium 
to predict whether the ECs are likely to remain adherent on the surface.   
3.3 Materials and methods 
3.3.1 Stent geometry modeling & meshing 
The stent geometry used in this study was based on the peripheral nitinol stent 
Cordis S.M.A.R.T.®  (Johnson & Johnson), with unconstrained dimensions 6 mm O.D. x 
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30 mm length.  The solid model was discretized into a finite element mesh using ANSYS 
MeshingTM 14.5 software (SAS).   
Dimensions and design pattern of stents 6 mm diameter x 30 mm length were 
acquired using an upright Leica DMRB microscope and QCapture Pro 7 software, as 
well as direct measurement of stent wall thickness.  The stent geometry was generated 
using SolidWorks (Dassault Systèmes) and ANSYS DesignModeler (SAS).  The stent was 
then implanted into vessel of approximately 5 mm diameter using Boolean subtraction.  
For the steady-state simulation, one half of the tube was modeled.  To reduce 
computation time for transient simulations, a section of the stent and vessel equal to 
one-sixth circumference of the tube was modeled (Figure 3.1A), because the stent pattern 
repeats in 6 circumferential sections.   
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Figure 3.1:  Modeled stent geometry and discretized mesh. 
(A) 3-D modeled geometry of one-sixth stent circumference.  Scale bar is 12 cm.  (B) 
Close view of mesh shows high density of mesh elements near outer diameter, created 
by inflation of the mesh necessary for accurately resolving the boundary layer. Scale 
bar is 100 μm. 
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The solid model was discretized into a finite element mesh using ANSYS 
MeshingTM 14.5 software (SAS).  Preliminary simulations showed that it was most 
important to resolve small distances near walls to capture boundary layer changes 
(Figure 3.1B).  Elements near the wall were highly anisotropic to resolve wall shear 
stresses well without prohibitive computational cost.  Inflation on the tube outer 
diameter was used to resolve the boundary layer.   
3.3.1.1. Steady-State Mesh Characteristics 
For the steady-state simulation, a fully-developed parabolic inlet profile was 
used.  A combination of wedge and tetrahedral elements comprised the mesh, which 
had a total of 22.5 million elements and 4.2 million nodes.  The mesh was refined until 
increasing the number of elements did not significantly change simulation outcomes.   
3.3.1.2. Transient Mesh Characteristics 
For transient simulations a long entrance length tube (12 cm) was added to the 
inlet of the stent for flow development.  A combination of wedge and tetrahedral 
elements comprised the mesh, which had a total of 18.7 million elements and 7.2 million 
nodes.  Orthogonal quality of the mesh was 0.87 ± 0.17 (mean ± standard deviation).  The 
mesh was refined until increasing the number of elements did not significantly change 
simulation outcomes.   
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3.3.2 Simulation parameters 
Given the arterial flow conditions, we modeled blood as a Newtonian fluid as 
others have done[100,104,153] with density ρ = 1060kg/m3 and dynamic viscosity μ = 0.004Pa 
s-1.  The vessel was modeled as a rigid cylinder with stent struts contacting the inner 
diameter and protruding into the lumen.   
We calculated two time-averaged parameters: oscillatory shear index (OSI)[154,155], 
and time-averaged wall shear stress (WSSav)[155], over the cardiac cycle simulated.  These 
were defined as:  
            
       
 
 
    
 
    
         
       
 
 
       
 
 
   
Where τy is the vector component of the shear stress tensor in the axial direction 
of flow (y), τw is the total WSS magnitude, t is time, and T is total simulation time (one 
cycle period).  By this definition, the range of OSI is 0 to 0.5. 
3.3.3 Input waveforms 
3.3.3.1 Steady-state conditions 
For the steady-state simulation, a fully developed parabolic velocity profile was 
imposed at the inlet.  The inlet profile for tube with radius R varied with radius position 
r by the following equation: 
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For the steady-state simulation, the average velocity vavg was a constant and was 
set at 33.6 cm/s.  This average velocity was chosen so that the total flow rate would be 7 
mL/s.  We had established this flow rate for the porcine carotid artery in a preliminary 
exploratory surgery using an ultrasonic flowmeter (Transonic). 
3.3.3.2 Transient conditions 
For the transient conditions, the velocity profile at the stent inlet should be the 
appropriate Womersley profile for unsteady flow at each time point.  The complexity of 
the Womersley profile did not allow us to directly use this solution as an input.  To 
achieve the Womersley profile, a “blunt” velocity profile, more flat than a parabola, was 
imposed at the tube inlet and allowed to develop over 12cm.  This blunt velocity profile 
was closer to the target Womersley profile than a parabola, allowing the flow to develop 
more quickly.  Flow was confirmed as fully developed by running a simulation with a 
different inlet velocity profile and verifying that the velocity profile at stent inlet did not 
vary significantly at any time point.  The inlet profile for tube with radius R varied with 
radius position r by the following equation:  
                 
  
  
  
3.3.3.3 Time-varying inlet waveforms 
To model the normal human common carotid waveform, we referenced an 
archetypal waveform[156].  To model the carotid waveform under conditions of 
hypertension and reduced compliance, we used trends reported previously in the effect 
(4) 
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of vessel compliance on carotid artery flow waveforms[157].  We fit each of these 
waveforms to a Fourier series representation.  CFD simulations were run using ANSYS 
CFX 14.5 (SAS) to solve the time-dependent Navier-Stokes equations; one complete cycle 
was simulated. 
3.3.3.4 Normal human carotid waveform 
To model the normal human common carotid waveform, we referenced the 
archetypal waveform published by Holdsworth et al[156].  We then fit this waveform, 
with a stated period of 0.917 seconds (and Womersley number 3.6), to a Fourier series 
model with 8 pairs of sine and cosine terms.  The frequency used in the Fourier series 
model, 6.842, was related to the period as 2π/period. 
3.3.3.5 Reduced Compliance Hypertension Waveform 
To model the carotid waveform under conditions of hypertension and reduced 
compliance, we used trends reported previously in the effect of vessel compliance on 
carotid artery flow waveforms[157].  Masuda et al. reported that when vessel compliance 
was reduced, there was a decrease in the maximal flow of the carotid velocity waveform 
and an increase in the second peak.  We modeled the shape of the reduced (75% of 
normal) compliance flow waveform and matched the period to our model of the normal 
carotid waveform.  We also adjusted the peak velocity so that the relationship between 
the normal and reduced compliance waveform modeled the relationship reported by 
Masuda[157].  Knowing that the waveform period is well within the range of 
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interindividual variability[156,158], and that the diameter of the vessel modeled has a 
strong relationship to the peak velocity, we matched these parameters to our normal 
model so as to isolate the specific effects of the compliance change in our simulation. 
This waveform was not able to be fit well with a single Fourier series.  We fit this 
waveform to a piecewise function such that a unique Fourier series described each peak.  
The frequency used in the Fourier series fits here varied and was not related to the 
period in a straightforward way, in an effort to achieve the best fit. 
3.3.3.6 Inlet Waveforms – Fourier Series Goodness of Fit 
To quantitatively measure the adequacy of the Fourier reproductions, we 
measured the variance of the wave and compared to the variance of the Fourier series.  
For each captured curve having m ordinates with a mean value of ym, we used the 
following equation: 
          
 
 
  
 
   
      
  
The percent of the variance represented by the Fourier series was measured by 
the ratio of the cumulative variance of the Fourier series (Vs) to the total variance of the 
raw velocity waveform (Vt).  For the normotensive waveform, the percent variance 
captured by the addition of each pair of harmonic terms is shown in Figure 3.3. 
3.3.4 Computational Simulations  
CFD simulations were run using ANSYS CFX 14.5 (SAS) to solve the time-
dependent Navier-Stokes equations.  The total time simulated was equal to one 
(5) 
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complete cycles of the waveform (period 0.917 s) with a timestep such that the Courant # 
was <20.  Each timestep was iterated 8 times or until residuals for were less than 10-5, 
whichever came first.   
3.4 Results 
3.4.1 Simulation convergence 
For the steady-state simulation, acceptable convergence was observed.  Residuals 
for the axial momentum terms converged to the order of 10-6, and residual terms for the 
other two momentum directions converged to the order of 10-5.  For both the 
normotensive and hypertensive simulations, acceptable convergence was observed.  
Residuals for the axial momentum terms converged to the order of 10-7 and 10-6 for the 
normotensive and hypertensive cases, respectively, and residual terms for the other two 
momentum directions converged to the order of 10-5 for both cases.   
3.4.2 Time-varying input waveforms 
Reconstruction of the healthy human carotid waveform with a Fourier series 
consisting of the first eight harmonics showed only 0.2% variation from the template 
waveform (Figure 3.2A).  Comparison of the Fourier series with the healthy human 
carotid waveform showed that 8 harmonics accounted for 99.8% of the variance (Figure 
3.3).  The error is therefore much less than the variability between individuals [156,159].  
The piecewise Fourier series model of the carotid waveform in hypertension / reduced 
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compliance (Figure 3.2B) also showed 0.3% variation from the template waveform, with 
7 harmonics for each piecewise section accounting for 99.7% of the variance. 
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Figure 3.2:  Input waveforms for normotensive and hypertensive conditions. 
(A) Input waveform, Fourier Fit F(t), fit to waveform V-avg of normal carotid flow 
experimentally determined by Holdsworth et al. [156].  (B) Normal carotid waveform 
Fourier fit F(t) from (A) and reduced compliance (75% of normal) hypertension 
waveform Fourier fit F(t).   
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Figure 3.3:  Fit of the Fourier series by number of paired terms. 
Cumulative ratio of the variance of Fourier series fit (Vs) to the total variance (Vt) of 
the healthy archetypal human carotid waveform of Figure 1.  Eight harmonics results 
in a Vs/Vt ratio of 99.8%. 
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3.4.3 Shear stresses and OSI 
We examined shear stresses on the stent surface as well as the unstented vessel 
inlet and a representative exposed vessel wall segment in the middle of the stent.  For 
both the normotensive and hypertensive cases, the velocity profiles at the stent inlet 
agreed well in shape with the Womersley solution and captured the key features of the 
Womersley solution.  The blunted profile we used worked better for profile 
development than a parabolic inlet profile.  By making slight changes to the inlet profile 
shape and confirming identical profiles at the stent inlet, we confirmed that the flow was 
fully developed at the stent inlet. 
3.4.3.1 Steady-state simulation 
Computational simulations of steady-state flow through the stent geometry 
revealed large variations in shear stress experienced by different stent surfaces (Figure 
3.4).  On lateral surfaces of the stent, a large shear stress gradient exists, and shear 
stresses vary by one order of magnitude along the width of the strut.  Steady-state shear 
stresses on key surfaces are reported in Table 3.1. 
For the steady-state simulation, OSI was not calculated as there was no time 
component.  We instead calculated a degree of flow reversal caused in the steady-state 
condition due to flow patterns around the stent geometry.  Based on a measure of the 
fluid volume with a negative axial velocity, 3.6% of the fluid volume flowing through 
the stent experienced flow reversal.  
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Figure 3.4: Contour plot of total wall shear stress on stent under steady-state flow 
condition. 
Contour plot of total wall shear stress on stent under steady-state flow condition and 
baseline shear stress approximately 20 dyn cm-2.  Flow direction denoted by arrow.  
Note lateral surfaces of stent struts experience a high shear stress gradient and vary 
from approximately 5 to 50 dyn cm-2 along the width of the surface. 
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3.4.3.2 Normal human carotid waveform 
Lateral and lumenal surfaces of the stent were exposed to a wide range of shear 
stresses and circulation patterns.  Instantaneous shear stresses were calculated at points 
of interest in the cardiac cycle, including systolic acceleration (Sa), just before peak 
systole as the flow starts to level, peak systole (Sp), systolic deceleration at the local 
minimum following peak systole (Sd), and diastole (D) at the local maximum in diastole 
(Figure 3.5).   
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Figure 3.5:  Instantaneous total wall shear stress (WSS) contours on stent and 
surrounding vessel during key points of normotensive waveform. 
Key timepoints are systolic acceleration (Sa), peak systole (Sp), systolic deceleration 
(Sd), and diastole (D) in a normal human carotid artery.  Flow direction is shown by 
the arrow and is identical in all panels.  The flow waveform and the corresponding 
time points in the cardiac cycle are shown at bottom. 
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As expected by its greater protrusion into the vessel lumen, average shear stress 
over the entire cycle was greatest on the lumenal surface (4.92 Pa), compared to 1.81 Pa 
for the inlet, which represents an unstented vessel wall.  In contrast, shear stresses on the 
lateral surfaces in the middle of the stent length were lower (between 1.1-1.2 Pa).   
Examining vector components of the shear stress tensor in the axial direction of 
flow allows positive and negative shear stresses to be distinguished with respect to the 
flow direction.  Shear stress contours of axial wall shear stress (WSSaxial) show areas 
with negative flow.  At the cardiac cycle global flow maximum of peak systole, shear 
stresses on nearly all surfaces are positive in the axial direction (Figure 3.6A), with small 
areas of recirculation occurring in corner areas protected by “zig-zag” pattern of the 
stent.  In contrast, in the cardiac cycle global flow minimum, shear stresses on nearly all 
surfaces are negative in the axial direction (Figure 3.6B), with only small areas of 
positive shear stress in locations mirroring those protected areas seen in Figure 3.6A. 
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Figure 3.6:  Instantaneous axial wall shear stress (WSSaxial) contours  in normotensive 
condition. 
(WSSaxial) contours on stent and surrounding vessel during (A) cardiac cycle global 
maximum flow (0.16 s) and (B) global minimum flow (0.40 s) in a normal human 
carotid artery.  Positive flow direction is shown by the arrow and also marks the 
positive axis with respect to WSSaxial. 
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Average shear stresses and OSI on specific surfaces are reported in Table 3.1., 
and surfaces of interest are labeled on a stent diagram in Figure 3.7.  All values represent 
an average over the surface area of interest.  Close examination of shear stress contours 
(Figure 3.8A) reveals that shear stresses vary over many strut surfaces both axially and 
radially.  Shear stresses vary most on strut lateral surfaces.  The variation ranges from 
nearly 0.5 Pa at the vessel wall and near 5 Pa at the lumenal edge of the lateral struts.  On 
these lateral struts, shear stresses reach minimum values at the vessel wall, but are also 
decreased at the “inside” corner of each zig-zag shape of the stent, where flow 
reattachment is hindered in comparison to the more open spaces between struts. 
The OSI at the vessel inlet, before the flow reaches the stent, is non-negligible 
(0.14, Figure 3.8B).  OSI on the lumenal stent surface is less at 0.11, whereas OSI on the 
first row of struts is higher, 0.14-0.15.  Oscillations are increased on stent faces and 
exposed vessel walls in the middle of the stent length, with 0.17 OSI and 0.21 OSI, 
respectively.  The high OSI on the vessel wall is expected and correlates with flow 
separations and low shear stresses previously reported around stents[102,104].  Non-zero 
values of OSI are consistent with the presence of negative axial shear stress representing 
flow reversal in the global flow minimum of the cardiac cycle. 
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Table 3.1: Time-averaged shear stress and oscillatory shear index on specific surfaces 
of interest. 
  
Steady-State 
Condition 
Normal Human  
Carotid Waveform 
Hypertension/Reduced 
Compliance 
Surface WSS (Pa) WSSav (Pa) OSI WSSav (Pa) OSI 
Strut A first row 2.38 2.17 0.14 2.08 0.05 
 
mid-stent 1.47 1.19 0.17 1.17 0.09 
Strut B first row 1.91 1.51 0.16 1.47 0.07 
 
mid-stent 1.47 1.11 0.17 1.09 0.10 
Inlet C 
 
2.09 1.75 0.14 1.76 0.04 
Lumenal D 5.63 4.92 0.10 4.80 0.01 
Wall E 
 
0.63 0.57 0.21 0.55 0.15 
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Figure 3.7:  Schematic of key named surfaces referenced in Table 3.1. 
(A) Upstream lateral surface, pictured in first row of struts and also mid-stent 
(yellow).  (B)  Downstream lateral surface, pictured in first row of struts and also mid-
stent (magenta).   (C) Inlet portion of vessel (green).  (D) Lumenal surface of stent 
(orange); surface extends throughout length of stent.  (E)  Vessel wall between struts, 
mid-stent (gray).  Note that specific stent struts A and B repeat multiple times around 
the circumference in the schematic, which is an instance transform to depict half the 
stent; one-sixth of the stent was modeled, so surfaces repeat.  Inset:  Close-up view of 
upstream and downstream lateral strut surfaces A and B.  Flow direction is indicated 
by arrow. 
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Figure 3.8:  Contour plots of (A) time-averaged Wall shear stress (WSSav) and (B) 
oscillatory shear index (OSI) on stent surfaces in a normal human carotid artery. 
Flow direction is shown by the arrow and is identical in both panels. 
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3.4.3.3 Reduced compliance hypertension waveform 
In the simulation of reduced compliance and hypertension, many trends were 
similar to the normal carotid simulation.  Total flow integrated over the cardiac cycle 
differed by only 1% from the normotensive waveform, so the differences in shear stress 
and OSI are attributed to the different shape of the waveform rather than an overall shift 
in flow.  Instantaneous shear stresses were calculated at Sa, Sp, Sd, and D in the 
respective waveform (Figure 3.9), and time points were similar but not identical to those 
of the normal carotid simulation.  Average shear stress remained highest on the lumenal 
surface, at 4.8 Pa (vs 4.92 Pa under normal conditions).  Shear stresses on the lateral 
surfaces in the middle of the stent length remained lower than on the lumenal surface - 
approximately 1.1-1.2 Pa for both hypertensive and normal conditions (Figure 3.10A).  
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Figure 3.9:  Instantaneous total wall shear stress (WSS) contours on stent and 
surrounding vessel during key points of hypertensive waveform. 
Key timepoints are systolic acceleration (Sa), peak systole (Sp), systolic deceleration 
(Sd), and diastole (D) in a carotid artery with reduced compliance.  Flow direction is 
shown by the arrow and is identical in all panels.  The flow waveform and the 
corresponding time points in the cardiac cycle are shown at bottom.   
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While minimal changes to the shear stresses were seen from the normotensive to 
the hypertensive condition at the locations in the waveform chosen, greater changes 
were observed in OSI.  OSI on the vessel inlet, before the flow reaches the stent, is 
minimal (0.04, Figure 3.10B).  OSI on the lumenal stent surface is much lower (0.01) and 
OSI on the first row of struts (0.05-0.07) is approximately half that of the normotensive 
case as well.  OSI is reduced from values obtained for the normotensive case, on stent 
faces and exposed vessel walls in the middle of the stent length, with 0.09 OSI and 0.15 
OSI, respectively.   
  
 83 
 
Figure 3.10:  Contour plots of (A) time-averaged Wall shear stress (WSSav) and (B) 
oscillatory shear index (OSI) on stent surfaces in a human carotid artery with reduced 
compliance. 
Flow direction is shown by the arrow and is identical in both panels.   
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3.5 Discussion 
The results of this study indicate that the blood-contacting surfaces of a carotid 
stent are exposed to a range of shear stresses, and varying degrees of flow reversal.  
Average shear stresses are close to 5 Pa at the highest, on the lumenal stent surfaces and 
are similar in both normal and hypertensive cases.  In contrast, OSI on all stent surfaces 
is lower by approximately half in the hypertensive case, indicating a lesser degree of 
flow reversal.  
To date, only the shear stresses on the walls of a stented vessel have been 
reported[101-104,150], not shear stresses on the surface of the stent itself.  While average shear 
stresses on the vessel walls of a stented vessel (0.5-0.6 Pa in these models) are typically 
lower than on an unstented vessel (1.8-1.9 Pa in these models), we find that shear 
stresses on the stent itself are generally higher than the 1.8 Pa shear stress calculated on 
the adjacent unstented vessel wall.   
The carotid waveform model of hypertension studied here is for a vessel with 
75% of the original vessel compliance.  This is representative of moderate hypertension.  
In a patient population with blood pressure exceeding 160/90 mmHg, the vessel 
compliance in large arteries is reduced to 80% of the value found with age-matched 
normotensive individuals[152].  Vessel stiffness increases with age, both with and without 
hypertension[160-162].  When the elasticity of a vessel is reduced, the timing of the reflected 
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waves is changed and results in a decrease in the maximum flow velocity as well as an 
increase in the second peak of the flow waveform[157]. 
EC adhesion in vivo is influenced by the shear stresses on implanted stents as it 
relates to our goal of endothelializing peripheral stents.  We have previously shown that 
fully spread ECs are retained on uncoated Ti surfaces under sustained shear stresses up 
to 10 Pa[126].  In this study, the highest time-averaged shear stress in a stented healthy 
carotid artery is 4.92 Pa and is on the stent’s lateral surface; this is below our previously 
studied long-term shear stress of 10 Pa, and we anticipate that seeded ECs will be 
retained under these conditions.  In comparison, the highest transient shear stress on the 
stent surface is 27.5 Pa, on the lateral surface, during the healthy cardiac cycle.  In the 
model of moderate essential hypertension, the highest transient shear stress on the stent 
surface is 26.5 Pa, on the lateral surface.  The highest time-averaged shear stress is 4.80 
Pa, on the lateral surface.  We have shown previously that even ECs which are not fully 
spread are approximately 90% retained under short-term shear stresses of 30 Pa after a 
15-minute period of attachment[126].  Based on this result, we would expect that most ECs 
seeded onto a stent at the point of care to be retained when deployed into a carotid 
artery under these normotensive or hypertensive conditions, despite a short period of 
attachment in our seeding method.  Further supporting this, we have observed good 
coverage of cells in preliminary in vivo experiments.   
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Stenting of the vessel increases OSI on vessel endothelium both within and 
slightly downstream of the stent; OSI in an unstented common carotid artery has 
previously been reported from zero to 0.10, [154,163], but was calculated at 0.14 on the 
unstented inlet tube under our ‘normal’ flow conditions.  This non-negligible OSI can be 
explained by looking at the Womersley velocity profile.  For a time period around the 
flow minimum, velocity near the wall is reversed despite an overall positive flow ( 
Figure 3.11).   
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Figure 3.11: Velocity profiles at t = 0.4 s, near the cardiac cycle flow minimum, 
in normotensive carotid model. 
Inlet velocity (red) is a blunt power law profile as described, and develops into 
Womersley solution just before the stent (blue).  Profiles are shown for half of the 
stent diameter, from center position 0 to full radius R at 0.00275 m.  Although overall 
flow is positive, velocity near the wall is negative, contributing to a non-zero OSI for 
the normotensive simulation. 
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Although the shear stress is not greatly changed on stent surfaces from 
normotensive to hypertensive conditions, the OSI changes much more.  The overall 
integrated flow is very similar, and the magnitude of the peak systole is similar between 
the two waveforms.  The biggest difference then is in the shape of the two waveforms.  
In particular the range or fluctuation between the post-sytole global flow minimum and 
the local maximum in diastole is much smaller in hypertension, representing a lesser 
degree of oscillation. 
Wall shear stress levels are also expected to impact function and gene expression 
of any endothelium seeded onto stent surfaces.  Sustained “high” WSS of 10 Pa 
promotes a different phenotype than normal WSS (~2 Pa) or low WSS (<0.4 Pa)[164].  
Specifically, sustained high wall shear stress promotes expression of an anti-coagulant 
and anti-inflammatory phenotype, and promotes EC proliferation.  A proliferative 
phenotype could be advantageous for the described application of endothelial seeding 
for a vascular stent, as EC proliferation could help seeded ECs compensate for any 
incomplete stent coverage and local vessel denudation following pre-stenting balloon 
angioplasty.  Anti-coagulant and anti-inflammatory factors secreted by the cells would 
further the desired outcome of EC seeding, which is reducing stent thrombosis and 
hyperplastic restenosis. 
The degree of flow reversal impacts endothelial function[165].  OSI is correlated 
with intimal thickening[154] and in vivo measures of EC inflammatory phenotype such as 
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NF-κB expression[166], expression of monocyte chemoattractant protein-1[167], and 
expression of platelet-derived growth factors which promote EC turnover and smooth 
muscle cell infiltration of the subintimal space[168].  However, OSI alone has been found 
not to be highly predictive of EC inflammatory activation in vitro[163].  While an OSI 
threshold that may represent activation of an inflammatory phenotype or intimal 
thickening has not been identified, cells on stent surfaces with high OSI may have higher 
levels of inflammatory markers and be more likely to exhibit an inflammatory 
phenotype than ECs on a normal artery of similar dimensions.   
The presented study has some limitations and inherent assumptions.  The 
stented vessel is modeled as being rigid with a constant radius; we do not model 
‘pillowing’ of the vessel protruding into the lumen between stent segments[102], or local 
minor dilation of the stented portion of vessel, as might be expected by typical 
oversizing of self-expanding stents.  While arteries exhibit compliance, the assumption 
of rigid vessel walls for modeling likely resulted in a moderate overestimation of wall 
shear stresses compared with a distensible wall model[169] but was highly advantageous 
for practical concerns of computational time.  Vessel elastic expansion is expected to be 
limited by an implanted stent and is known to decrease with age[170], but any distension 
could potentially alter shear stresses and increase the degree of flow reversal, through 
the Windkessel effect.  The relationship between the hypertensive and normotensive 
conditions served to estimate the effects of vessel compliance due to changes in the inlet 
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waveform alone.  Despite these approximations and assumptions, the temporal changes 
within each waveform and the trends between healthy and hypertensive waveforms 
should still be representative of trends in the native environment.  While the values 
calculated in this study are specific to the stent geometry and flow conditions studied 
here, the trends are expected to remain the same from normal to hypertensive 
conditions.  Additionally, trends in the distribution of stresses among lateral and 
lumenal surfaces, and the higher shear stresses on struts near the stent inlet, are 
expected to be representative of and apply to many similar stent geometries. 
Future studies could include different vessel sizes and flow rates, to account for a 
greater range of inter-individual variability and alternate implantation sites (i.e. iliac 
artery, coronary artery).  Importantly, this study is the first to present information on 
hemodynamic conditions on a stent surface rather than only on the native vessel wall.  
This is important in predicting retention of ECs implanted onto stents, as well as making 
general predictions about expected phenotype of the ECs (inflammatory vs. healthy).  
The results also serve to predict differences in local conditions based on reduced vessel 
compliance in the hypertensive state, which apply to both the stent surface and the 
vessel surface. 
3.6 Conclusions 
In conclusion, our results show that the hemodynamic conditions on a carotid 
artery stent are expected to be conducive to retaining and supporting a seeded layer of 
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functional endothelium on an implanted stent surface, under both normal and 
hypertensive conditions.  These findings provide new insight in shear stresses and 
oscillations directly on the surface of an implanted stent, and inform future efforts to 
seed endothelium onto stents. 
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4. Point-of-Care Seeding of Nitinol Stents with Blood-
Derived Endothelial Cells 
Portions of the text and figures included in Chapter 4 have been submitted to 
Circulation for publication.  This article does not yet have a publication date; Circulation 
does not require permission for authors to reuse their own articles, but an optional grant 
of license may be obtained as soon as one was available via Rightslink®.   
4.1 Chapter synopsis 
This chapter describes the method proof of concept phase of developing a point 
of care method for seeding nitinol vascular stents with functional endothelium.  
Thrombotic and restenotic complications remain with vascular stents.  To ameliorate 
these complications we sought to develop a method for seeding nitinol stents within the 
delivery system immediately before implantation.  We machined hundreds of very small 
holes into the stent delivery system sheath surrounding a commercially made nitinol 
stent, to allow for exit of an infused cell suspension.  Blood-derived endothelial cells 
(ECs) were flushed through the stent delivery system and adhered to the stent as the 
suspension medium flowed outward through the holes.  ECs spread to cover the stent 
surface following 24 h culture in vitro under static or flow conditions.  After flow, ECs 
exhibited increased nitric oxide production; expression of genes KLF-2 and COX2 
trended upward from static baseline.  After 48 hours in vivo in a porcine model, 
autologous seeded ECs spread to cover the stent surface (n = 4).  ECs seeded onto 
commercial nitinol stents within minutes of expansion spread to form a functional layer 
 93 
in vitro and in vivo after 2 days, providing proof of concept that the infusion method of 
ECs into modified stent systems can feasibly be used at the point-of-care to seed a 
functional autologous endothelium. 
4.2 Introduction 
Percutaneous transluminal angioplasty and stent placement have revolutionized 
the treatment of coronary artery disease and peripheral vascular disease; however, 
restenosis at the intervention site remains a significant problem.  Stent failure is 
associated with thrombosis and intimal hyperplasia.  Intimal hyperplasia after 
percutaneous intervention is especially problematic in the peripheral arteries.  In the 
femoropopliteal arteries, approximately 50% of self-expanding stents occlude within two 
years[122,171].  Close to 20% of patients who receive carotid artery stents will suffer from 
re-occlusion of the stented vessels after only two years[123].   
Drug-eluting stents in coronary arteries have reduced stent restenosis rates[16,38], 
and have recently been approved for peripheral vascular indications[33].  Drug-eluting 
stents, however, are associated with a risk of late-stage thrombosis once the drug coating 
has dissipated[39,40], related to a lack of endothelium[172,173].  As an alternative, 
biorebsorbable stents of various materials are in clinical trials in the US, and some are 
approved for use in Europe[174], but it is unclear how restenosis rates compare to 
conventional treatment when no structural support remains, following full absorption of 
the device[54,55].  In order to reduce long-term thrombosis and intimal hyperplasia, 
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several strategies have been investigated to recruit circulating endothelial progenitor 
cells (EPCs) to cover stents.  Antibodies to CD34[73,74,175] and CD144[78], as well as RGD 
peptides[81], have been used to capture circulating EPCs.  However, among all circulating 
cells, these markers are not specific for EPCs and no single antibody specific to EPCs has 
yet been identified.  A capture strategy utilizing aptamers is under investigation but has 
not been tried in vivo and has not been shown to be specific to EPCs[85].  
Our overall goal is, prior to deployment, to coat nitinol stents with the patients’ 
own endothelial cells (ECs), derived from peripheral blood, to promote rapid 
endothelial coverage and thereby decrease the risks of stent thrombosis and in-stent 
restenosis.  This approach is different from the current drug-eluting devices, which 
inhibit smooth muscle cell (SMC) proliferation, but also inhibit EC growth on the stent 
and therefore inhibit vessel healing[47,125,176-183].  If a methodology of rapid 
endothelialization can be developed, the intrinsic anti-coagulant mechanisms of ECs 
should reduce the risk of stent thrombosis, and paracrine factors released by endothelial 
cells (e.g. nitric oxide) would inhibit SMC proliferation and intimal hyperplasia[61].  A 
method of rapid endothelialization therefore would have the potential to address both 
major failure modes of stenting: thrombosis and intimal hyperplasia. 
Previous approaches to directly seed metal stents with ECs prior to implantation 
have been limited by the use of immortalized or xenogeneic cell sources[63,64], pre-coating 
of the stent with potentially thrombogenic polymers or proteins, such as fibronectin[62,65-
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68], prohibitively long culture (>7 days) of the stent and cells together prior to stent 
deployment[64-67], and compression of an expanded stent back into a delivery catheter 
after seeding in its expanded state[64-66,71].  As such, these studies suffer from incomplete 
endothelial coverage, especially after recompression of the stent[64,71].  Furthermore, ex 
vivo culture in these studies proved to be impractical for translation of these methods 
into clinical practice.  An alternative strategy, targeting using magnetically tagged cells 
with local injection[72], is not practical for nitinol stents because nitinol is not 
ferromagnetic. 
As an alternative, we have invented a novel rapid seeding method 
(QuickSeedingTM), in which an EC suspension is infused into the stent delivery system to 
coat compressed nitinol vascular stents with blood-derived ECs 10 minutes prior to 
deployment.  This method eliminates the need to culture the stent and cells together for 
multiple days and manipulate the stent back into/onto a delivery catheter; instead, EPCs 
are isolated from peripheral blood, expanded as ECs ex vivo until needed, and then 
infused within minutes of deployment at the point-of-care.  This method was developed 
based on the following results.  We have shown that ECs attach to Ti without pre-
coating[126].  Second, nitinol stents are typically electropolished such that the outer 
surface is comprised of titanium oxide (TiO2) with no measurable nickel, and we 
established that ECs can also attach to nitinol stents without pre-coating[25,136].  Lastly, 
rapidly-seeded ECs spread quickly on Ti surfaces under fluid flow conditions in vitro 
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and in vivo to form a confluent lining that prevents thrombosis when implanted into the 
inferior vena cava of pigs[136].  Nitinol stents are used in the majority of peripheral cases 
because of the flexibility and shape memory of nitinol; superficial peripheral sites 
include carotid and femoral arteries[20].  The technology presented here applies to nitinol 
stents and therefore has the greatest potential for use in peripheral artery disease. 
For QuickSeedingTM nitinol stents, we use ECs derived from colony-forming cells 
[79] or late-outgrowth ECs [184] isolated from blood.  These ECs are phenotypically and 
functionally identical to vessel wall ECs[90] and can be derived from the blood of the 
patient who might need percutaneous angioplasty with stent placement[97].  We used 
ECs derived from human umbilical cord blood (hECs) for in vitro experiments because 
of their human origin.  For in vivo experiments, we use ECs derived from porcine 
peripheral blood (pECs), so that cell implantation is autologous for each individual pig. 
We test the following hypotheses: 1) modification of the sheath of a commercial 
stent delivery system with micropores enables rapid infusion seeding of compressed 
nitinol vascular stents with ECs at the point-of-care; 2) ECs remain adherent after stent 
deployment and under arterial fluid shear stress conditions; and 3) ECs are functional 
on the nitinol stent surface as measured by expression of anti-thrombotic genes and 
production of nitric oxide in response to fluid flow.  To test these hypotheses, we 
performed in vitro and in vivo experiments with ECs seeded onto nitinol stents.  Our 
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results support the feasibility of this method of personalized cell therapy at the point-of-
care. 
4.3 Materials and methods 
4.3.1 Isolation and culture of human umbilical cord blood-derived ECs 
(hECs) 
Umbilical cord blood samples were obtained from the Carolina Cord Blood Bank 
at Duke University per protocols approved by the Duke Institutional Review Board.  
The hECs for the study came from a total of three donors, and were cultured using 
standard practice in EBM-2 base medium plus EGM-2 SingleQuots (Lonza, Basel, 
Switzerland)[90].  Cells were used at passages 6-10 for in vitro studies.   
4.3.2 Isolation and culture of porcine peripheral blood-derived ECs 
(pECs) 
ECs for in vivo studies were isolated from porcine peripheral blood, as we 
described previously[136].  All experiments with swine were approved by the Duke 
University Institutional Animal Care and Use Committee (IACUC) and were conducted 
in accordance with the National Institute of Health Guidelines for the Care and Use of 
Laboratory Animals. Yorkshire swine (4 female, at an initial weight of approximately 35 
kg) underwent a blood draw 4 weeks prior to stent implantation to allow sufficient time 
for EPC isolation and amplification in culture.  The pigs were sedated with 
Acepromazine (1.1 mg/kg) and Ketamine (22 mg/kg) intramuscular.  Intubation was 
achieved with an endotracheal tube (30 cm length, 8 mm ID), and the pigs were 
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anesthetized with Isofluorane by mask.  The pigs’ groins were cleaned and sterilized 
with DuraPrep, and femoral vein access was obtained with a 5 F micro-introducer kit 
(Galt Medical) using the Seldinger technique[133].  After discarding the first 5 ml of blood, 
40 ml of blood were collected into syringes containing 20 USP/mL heparin.  This was 
followed by 1:1 dilution with Hank’s buffered salt solution (without CaCl2, MgCl2, 
MgSO4) and layered on equal volumes of Histopaque to create well-defined layers.  The 
mononuclear cell layer was collected as described previously[126] and plated into two 12-
well plates in full porcine EPC growth medium: EBM-2 base medium plus EGM-2 
SingleQuots without fetal bovine serum (Lonza) and 2% porcine serum (Gemini Bio-
Products).  Cells were used at passages 5-6 for in vivo studies. 
4.3.3 Characterization of ECs 
For flow cytometry, ECs were incubated with 0.025% trypsin (Lonza) for 3 min at 
37°C, and the reaction was neutralized with Trypsin Neutralizing Solution (Lonza).  
Cells were incubated at room temperature with FITC-conjugated or AlexaFluor 488-
conjugated antibodies for 30 min.  For hECs, markers CD31 and CD105 were tested as 
well as monocyte markers CD14 and CD45 (Serotec and BioLegend).  For pECs, porcine 
EC marker CD31 as well as porcine monocyte markers CD14 and CD45 were tested 
(Serotec and BioLegend).  Isotype controls (mouse IgG1 and mouse IgG2a; Serotec, 
BioLegend, Antigenix America) were used for each condition as appropriate.  Cells were 
rinsed and pelleted and fixed in 3.7% paraformaldehyde.  Approximately 9000 cells 
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were counted for each antibody on a FACSCalibur flow cytometry machine at the Duke 
University Flow Cytometry Shared Resource.   
4.3.4 Delivery system modification 
To enable radial flow of media and cells, micropores were drilled in the outer 
sheath of commercial nitinol-stent delivery systems (Cordis S.M.A.R.T.® CONTROL 
Vascular Stent System with 30 mm long and 6 mm diameter stents, Cordis Corporation, 
Bridgewater Township, NJ) using a 193 nm ArF excimer laser light in collaboration with 
Fraunhofer CMI (Brookline, MA).  Micropores were drilled in the sheath only in the area 
containing the stent, and four pores were clustered in each space between wire braid 
reinforcements of the sheath (Figure 4.2).  Micropores were evenly spaced 
circumferentially and each delivery system had approximately 5000 pores.  
Representative measurements of the major and minor diameters were made at the 
sheath outer surface (n = 4 systems) using phase contrast images and ImageJ software.  
A minimum of 50 pores were measured on each stent and averaged to obtain each n. 
4.3.5 Stent seeding 
A schematic of the cell seeding within the delivery system is shown in Figure 4.1.  
Prior to seeding, the gap between the delivery system sheath and the atraumatic distal 
tip was blocked by a rubber cap, so that the cell suspension was forced to exit through 
the circumferential holes.  Without this cap, the “path of least resistance” was the gap 
around the tip, and cell suspension passing through the specially designed micropores 
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was greatly reduced.  To begin QuickSeedingTM, air was removed from stent delivery 
systems by flushing 70% ethanol through the side-arm flushing port of the stent, which 
communicates with the stent but not the guidewire lumen of the device.  Following, 
DPBS with calcium chloride and magnesium chloride was flushed extensively through 
the same side-arm port to rinse away all ethanol.  The distal end of the delivery system 
was submerged in DPBS with calcium chloride and magnesium chloride  until seeding 
to prevent any re-introduction of air.   
For in vitro seeding experiments, adherent EPCs were labeled with the 
fluorescent dye Cell Tracker Orange CMRA (Invitrogen, Carlsbad, CA) in serum-free 
medium (15 min, 37°C).  For in vivo experiments, adherent EPCs were labeled with the 
long-term fluorescent dye PKH26 (Sigma-Aldrich) at a concentration of 4 μM (4 min, 
room temperature), and the reaction was stopped with porcine serum (Gemini 
Bioproducts, West Sacramento, CA).  Following labeling, cells were dissociated with 
0.25% trypsin (Lonza), and after dissociation the trypsin was neutralized with Trypsin 
Neutralizing Solution (Lonza).  Cells were counted, centrifuged for 5 minutes at 1500 
RPM and resuspended to a concentration of 1.5-2 x 106 cells/mL in DPBS with calcium 
chloride and magnesium chloride (Lonza).   
The 2 mL cell suspension was infused using a syringe and a syringe pump (0.4 
mL/min) until the entire solution was introduced.  Cell concentration was approximately 
2.0 ± 0.5 x 106 cells/mL for in vitro experiments and 5.0 ± 1.1 x 106 cells/mL for in vivo 
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experiments.  In both cases, we used the entire number of cells available, and similar 
flasks tend to hold more pECs than hECs due to cell size.  Higher concentrations of pECs 
for in vivo experiments also helped to compensate against loss of cells during 
deployment in the moving bloodstream, which we have not quantified.  After 
introduction of the entire solution, the delivery system sat stationary at room 
temperature for five minutes to enhance cell attachment prior to deployment.  
Depending on the experiment, stents were deployed into static medium, flow circuit 
tubing, or a porcine vessel. 
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Figure 4.1: Schematic of in-catheter seeding of ECs. 
Fluorescently labeled ECs (red) in a suspension are flushed through a stent delivery 
system from the proximal handle and adhere to a stent (gray) as the suspension 
medium flows outward through micropores in the delivery sheath (orange).  The gap 
near the distal tip of the delivery system is closed with a rubber “cap” (black). 
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4.3.6 In vitro flow experiments 
Stents for in vitro flow experiments were deployed into clear Tygon PVC tubing 
(McMaster-Carr, Elmhurst, IL) of 4 mm inner diameter.  Tubing sections containing 
stents were filled with flow medium and connected to the flow circuit.  The flow rate 
was increased gradually to the desired level over fifteen minutes.  Stented tubes were 
exposed to steady laminar flow for 24 hours to simulate physiological shear stress of 15 
dyn cm-2, as we have done previously[126].  The applied shear stress of 15 dyn cm-2 was 
achieved by applying a flow rate of 160 mL/min.  This imposed flow rate Q was 
calculated[185] according to  
Q = (τ • π • r^3) / (4 • μ) 
where μ is the fluid viscosity at 37°C (0.035 g cm-1 s-1),  τ is the desired wall shear stress 
(15 dyn cm-2), and r is the tubing radius (0.2 cm).  Medium used for flow experiments 
was EBM-2 base medium plus EGM-2 SingleQuots (Lonza), with 3% (by weight) dextran 
added (Fisher Scientific), to increase the viscosity from standard medium and 
consequently reduce the flow rate while maintaining the desired shear stress.  Medium 
was sterile filtered after addition of Dextran. 
4.3.7 Nitric oxide quantification 
To quantify nitric oxide (NO) production by ECs under flow and static 
conditions in vitro, we directly measured the primary oxidation product nitrite (NO2-) in 
150μL medium samples collected from the static control flask and flow circuit reservoir 
(1) 
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and 0 and 24 h in 5 experiments.  Samples were frozen at -80°C after collection until 
analysis.  Nitrite is a commonly used surrogate of NO availability[126] and has been 
shown to reflect changes in NO bioavailability following physical stimuli more 
effectively than measuring nitrate (NO3-) or the combined quantity of nitrite and nitrate 
(NOx)[186].  Nitrite concentration was measured by chemiluminescence with an 
Ionics/Sievers Nitric Oxide Analyzer (NOA280; Sievers Instruments, Boulder, CO) as 
described previously[126].  The total amount of nitrite produced was calculated as the 
product of concentration times the total volume of the medium (30 mL for flow circuit or 
10 mL for static control), while adjusting for volume lost from taking samples. 
4.3.8 Immunohistochemistry, fluorescent microscopy, and image 
analysis 
EC-coated stents for imaging were fixed in 3.7% buffered formaldehyde (Ricca 
Chemical) and permeabilized with 0.1% TritonX-1000 (Sigma-Aldrich).  Cells were 
blocked in 10% goat serum and incubated with mouse anti-human CD31 antibody 
(Invitrogen) diluted 1:100.  Following, stents and cells were incubated with the 
secondary antibody goat anti-mouse IgG AlexaFluor 488 (Invitrogen), diluted 1:500.  
Nuclei were counterstained with Hoechst 34580 (Invitrogen), diluted 1:1000.  
Fluorescent microscopy was performed with an inverted microscope (Leica) with a 
monochrome digital camera (Qimaging, Surrey, BC). 
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4.3.9 Quantitative RT-PCR 
Following 24 h flow or static culture, cells were released from stents with trypsin, 
and total RNA was isolated for gene expression analysis (RNeasy Plus Micro Kit, 
Qiagen).  Quantitative RT-PCR was performed (iScript cDNA Synthesis Kit and iQ SYBR 
Green Supermix; Bio-Rad) as described previously[90,187] with the Bio-Rad MyIQ iCycler 
to evaluate expression of antithrombotic genes COX2 and eNOS, transcription factor 
KLF-2, and inflammatory marker VCAM-1.  The housekeeping gene glyceraldehydes 3-
phosphate dehydrogenase (GAPDH) served as endogenous control to target gene 
expression, and cells grown in culture flasks under normal conditions provided 
reference RNA.  To determine relative gene expression the 2^ΔΔCt method was used, 
modified for primer efficiency[188].  Efficiency of each primer was measured and used to 
find ΔΔCt.  Measured primer efficiencies were 86% for both KLF-2 and GAPDH, 80% for 
VCAM-1, and 100% for both eNOS and COX2.  The forward and reverse primers used 
based on the gene sequence of interested were as follows for each gene respectively: 
 (a) COX2: 5’-TGA GCA TGT ACG GTT TGC TG-3’ and 5’-TGC TTG TCT GGA 
ACA ACT GC-3’;  
(b) eNOS: 5’-GTG ATG GCG AAG CGA GTG AAG-3’ and 5’CCG AGC CCG 
AAC ACA CAG AAC-3’; 
(c) KLF-2: 5’-GCA CGC ACA CAG GTC AGA AG-3’ and 5’-ACC AGT CAC AGT 
TTG GGA GGG-3’; 
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(d) VCAM-1: 5’-GGG CTT TCC TGC TGC GAA-3’ and 5’-AAG AGG CTG TAG 
CTC CCC G-3’ 
(e) GAPDH: 5’-GAC CCC TTC ATT GAC CTC AA-3’ and 5’-CAT GGA CTG 
TGG TCA TGA GC-3’ 
Melting curves were obtained after each reaction to verify that only the target 
cDNA was amplified. 
4.3.10 Cleaning and re-compression of stents 
To conserve the stents specially-machined stent delivery systems, stents and 
delivery systems were cleaned and re-used, for in vitro experiments only.  All stents 
used for in vivo studies were new and were not re-used.  After cells were released from 
each stent for RNA isolation as described below, stents were cleaned by sonication in 
Alconox soap solution, rinsed thoroughly in deionized water, then sonication in 70% 
ethanol.  Delivery systems were cleaned by flushing through of Alconox soap solution, 
deionized water, then 70% ethanol.  To allow re-use of the specially modified delivery 
system sheaths (for in vitro studies only), the tip of the delivery system was cut off to 
facilitate re-loading, and the inner catheter lumen was blocked with cyanoacrylate 
adhesive to prevent fluid escaping through the inner catheter rather than the higher-
resistance infusion holes.  Stents were recompressed to the delivery system diameter 
using a concentric stent compression device (model RMC, Blockwise Solutions) and 
pushed into an empty delivery system.  The delivery system end was then closed off 
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around the outer sheath with a rubber cap, again to force the cell infusion to exit 
through the machined holes rather than the end of the sheath.  Delivery systems were 
gas sterilized prior to use (18 h, 55°C) 
4.3.11 Stent implantation in swine 
All experiments with swine were approved by the Duke University Institutional 
Animal Care and Use Committee and were conducted in accordance with the National 
Institute of Health Guidelines for the Care and Use of Laboratory Animals.  Pig weight 
at the time of the stenting procedure was 38.0 ± 2.0 kg.  For pre-operative 
anticoagulation, each pig received a loading dose of 300 mg clopidogrel by mouth two 
days prior to the stent implantation procedure.  On the day of implantation, Clopidogrel 
75 mg was given orally and every day following until the explantation and sacrifice.  
Additionally, 325 mg aspirin was given to each pig by mouth beginning two days before 
surgery and continuing every day until explantation and sacrifice.   
On the day of stent implantation, the pigs were sedated with Acepromazine (1.1 
mg/kg) and Ketamine (22 mg/kg) intramuscular.  Intubation was achieved with an 
endotracheal tube (30 cm length, 8 mm ID), and the pigs were anesthetized with 
Isofluorane by mask.  The pigs’ groins were cleaned and sterilized with DuraPrep, and 
right femoral artery access was obtained with a 5 F micro-introducer kit using the 
Seldinger technique[133].  An 8F introducer sheath was placed, and 200 IU heparing/kg 
administered.  The anatomy was navigated using an 0.035” guidewire and 5F 
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angiographic catheter, under fluoroscopic visualization with a Siemens Siremobil 
Compact C-arm.  The bicarotid artery was engaged and limited angiography was 
performed to verify anatomy with ISOVUE infused contrast agent (Bracco).  A long 
sheath was exchanged for the short sheath to support subsequent balloon and stent 
delivery, and an additional 100 IU heparin/kg administered.  An angioplasty balloon (6 
mm diameter x 40 mm length) was inflated in the common carotid artery at a pressure of 
1-4 atm for 30-60 sec.  Following removal of the balloon catheter, the stent delivery 
catheter was advanced and the stent deployed by retraction of the outer sheath using the 
handle.  Following deployment of each stent, angiography was performed to verify 
good stent apposition and placement.  Each pig received both a bare control stent and a 
cell-seeded stent (6 mm diameter x 30 mm length), implanted in randomized fashion 
into right and left carotid arteries.  Therefore, balloon angioplasty, stent deployment, 
and angiography were repeated for the opposite common carotid artery so that each pig 
received a total of one control stent and one stent seeded with its own autologous pECs.  
Following the stent procedure, devices and sheaths were removed and pressure held on 
the puncture site until hemostasis was achieved.  
4.3.12 Safety of cell-seeding procedure 
A gross neurological exam was performed before and after the procedure after 
the anesthesia had worn off.  The exam was repeated every 24 hours until sacrifice.  Each 
pig’s alertness was assessed and spontaneous movements and gaze evaluated for 
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lateralizing behavior.  Additionally, the pig’s blink responses were tested and their 
reaction to tactile stimulation on their right and left sides.   
4.3.13 Stent explantation 
Two days after stent implantation, pigs were sedated, intubated, and 
anesthetized as described for stent implantation.  The carotid arteries were exposed 
following sharp and blunt dissection and heparin was administered (200 IU/kg) waiting 
a minimum of 5 minutes before clamping and explanting the vessel.  The vessels 
containing stents were explanted after clamping, in a randomized order (control vs. cell-
seeded), and immediately rinsed with DPBS.  A small portion of stent was removed with 
scissors and placed into culture medium to test for cell metabolism with the CCK-8 
Assay (Sigma-Aldrich, St. Louis, MO).  The remaining vessel and stent were then placed 
in 3.7% paraformaldehyde for fixation for 30 minutes.  After fixation, the stent was cut 
with scissors and its inner surface examined for any gross clot before proceeding with 
fluorescent microscopy.  After the devices were explanted, the pigs were euthanized 
with Euthasol euthanasia solution (390 mg/mL pentobarbital sodium and 50 mg/mL 
phenytoin sodium at 1 mL/10 lbs)  
4.3.14 Cell viability on explanted stent segments 
A 10% solution of CCK-8 (Sigma-Aldrich) was added to each well containing 
small segments of control or pEC-seeded stents, and incubated at 37°C, 5% CO2.  
Absorbance was measured at 450 nm using a microplate reader (Thermo Scientific, 
 110 
Waltham, MA) after 3 h and 21 h.  The number of stent rows (a.k.a. crowns) was 
recorded for each piece to normalize for the size of the stent segment and associated 
surface area available to contain cells.  Absorbance at 3 h was subtracted from 
absorbance at 21 h to measure the cell metabolism over time for both cell-seeded and 
control stents. 
4.3.15 Fluorescent microscopy of explanted stent segments 
Following explantation and paraformaldehyde fixation, the stents were cut 
longitudinally to visualize the inner surface as stated previously.  The presence of 
PKH26-labeled ECs on stents was examined on an upright DMRB model microscope 
(Leica, Solms, Germany) with Qicam monochrome digital camera (Qimaging, Surrey, 
BC) and Image Pro Plus software (Leica).  Stent segments were also subsequently 
imaged on a Zeiss 780 upright confocal microscope (Zeiss, Oberkochen, Germany). 
4.3.16 Scanning electron microscopy (SEM) 
Following stent explantation, paraformaldehyde fixing, and fluorescent imaging, 
stents were additionally fixed in glutaraldehyde 2%, then dehydrated in graded ethanol 
and hexamethyldisilazane (HMDS).  Samples were sputter coated with gold for 30 sec 
and images taken with a XL30 Environmental SEM at 3-5 kV (FEI, Hillsboro, OR). 
4.3.17 Statistical analysis 
Since cells from the same source were used for a given flow experiment and 
static control, NO production was compared using a two-tailed paired t-test.  RT-PCR 
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data was analyzed with a one-sample t-test vs. 1.  CCK-8 metabolic activity assay was 
evaluated using a paired t-test.  Statistical analyses were performed using GraphPad 
Prism 5 (GraphPad, La Jolla, CA) and JMP 8 software (SAS, Cary, NC).  Values of p < 0.1 
were considered to be statistically significant for the CCK-8 assay, with a limited sample 
size of three stents.  Values of p < 0.05 were considered to be statistically significant for 
all other tests. 
4.4 Results 
4.4.1 EC isolation and characterization 
The isolated hECs and pECs exhibited characteristic endothelial cell cobblestone 
morphology.  Flow cytometry confirmed that the cell population was positive for EC 
markers CD31 and CD105.  Cells were negative for leukocyte markers CD14 and CD45.   
4.4.2 Delivery system micropore characterization 
Micropores drilled into in the delivery system were observed with phase contrast 
microscopy and found to be evenly covering the stent (Figure 4.2) (approximately 5,000 
pores per stent).  Micropores were repeatably oriented in groups of 4 between braided 
wire reinforcements in the sheath, which could not easily be drilled through.  
Micropores were nearly circular at the sheath outer surface as visualized by light 
microscope, with major diameter of 39.4 ± 0.9 μm and minor diameter of 32.4 ± 0.4 μm (n 
= 4 systems).  The minor diameter aligned along the direction of the stent axis. 
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Figure 4.2:  Light microscope image of holes machined in outer sheath of a commercial 
stent delivery system for the process of infusion seeding. 
Each delivery system had approximately 5000 holes over the area of the stent. 
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4.4.3 hEC coverage and spreading inside nitinol stents in vitro 
hECs QuickSeeded immediately before deployment were retained on the stent.  
Those hECs spread to cover the surface under both static and flow culture conditions.  
hEC surface coverage immediately after seeding (Figure 4.3A) was calculated as 55,000 ± 
9,500 cells/cm2 (n = 4).  Large areas of the stent surface were covered with a confluent 
layer (Figure 4.3B,D) after 24 hours under both static and flow conditions.  hEC 
confluence was confirmed by PECAM stain of cell junctions after 48 hours static culture 
(Figure 4.3C). 
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Figure 4.3:  hEC coverage and spreading inside nitinol stents in vitro. 
(A) Stent with hECs immediately following QuickSeedingTM in vitro.  Stain: 
CellTracker Orange (LifeTechnologies, Carlsbad, CA).  (B) Stent with hECs following 
QuickSeedingTM and 24 hours static culture viewed from the lumenal side.  Stain: 
CellTracker Orange.  (C) Stent with hECs following QuickSeedingTM and 48h static 
culture, pictured on lateral stent strut surface.  Stain: PECAM (green); Hoechst 34580 
(blue) (LifeTechnologies).  Note that curved stent surface causes some areas to be out 
of focus while others are in focus.  (D) Stent with hECs following QuickSeedingTM 
and 24 hours flow. Stent is viewed from outside through clear Tygon tubing of flow 
circuit (Stain: CellTracker Orange).  Unspread hECs can be observed adherent to the 
tubing (arrow), whereas cells on nitinol stent are spread. 
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4.4.4 Nitric oxide production 
We assessed NO levels by directly measuring nitrites in the cell culture medium 
and adjusting for respective fluid volume under flow and static conditions.  Nitrite 
levels showed that there was a significant increase of NO production in the flow 
condition as compared to the static condition, after 24 hours time (*p < 0.01, n = 5).  Total 
nitrite in the static condition was 0.41 ± 0.13 nmol, and total nitrite in the flow condition 
was 7.83 ± 1.97 nmol (Figure 4.4). 
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Figure 4.4:  Nitrite production of ECs seeded onto nitinol stents, following 24 hours 
flow or static culture (*p < 0.01, n = 5). 
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4.4.5 Gene expression 
ECs QuickSeededTM onto stents were exposed to static or flow conditions for 24 
hours and then evaluated for expression of several genes.  Expression of inflammatory 
marker gene VCAM-1 was unchanged from static to flow conditions.  In contrast, gene 
expression of eNOS was significantly downregulated in the flow condition (p < 0.005, 
one-sample t-test vs. 1).  Although expression of anti-thrombotic genes KLF-2 and COX2 
were upregulated, they did not reach statistical significance with a sample size of n = 6 
(Figure 4.5). 
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Figure 4.5:  Gene expression of ECs on stents following 24 hours flow. 
Values are normalized to static conditions (**p < 0.005, n = 6, one-sample t-test vs. 
mean of 1). 
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4.4.6 Safety of cell-seeding procedure in vivo 
All pigs survived the procedure without complications.  A neurological exam did 
not reveal any evidence of cerebrovascular accidents.  The pigs were alert and oriented 
after the procedures; their gait was normal and symmetric; spontaneous movements 
were of similar magnitude on the right and left side.  The pigs would blink to threat on 
the left and right and they did not exhibit gaze preference to either side.  Further, the 
pigs reacted to tactile stimulation on their right and left sides. 
4.4.7 pEC retention and spreading inside nitinol stents in vivo 
The autologous fluorescent pECs, which were seeded onto the nitinol stents ten 
minutes before surgery, were visualized on every one of the four cell-seeded stents after 
two days in vivo and were found to have spread on the stent surfaces to form confluent 
monolayers (Figure 4.6).  All pECs visualized on the cell-seeded nitinol stents were 
positive for fluorescent dye PKH26, supporting that these were the cells pre-seeded onto 
the stent and not colonized from the bloodstream or local vessel wall.  Following 
staining with Hoechst 34580 for nuclei, selected samples were imaged again.  Many 
extra nuclei were seen on both control and cell-seeded stents, but only cell-seeded stents 
were positive for EPC dye PKH26 (Figure 4.7).  SEM images revealed these to be 
leukocytes.  Both conditions had leukocytes visible on the surface; on the EC seeded 
stent these were on the ECs themselves.  SEM images showed good coverage of ECs on 
the seeded stent, and fibrous covering on the bare metal stent (Figure 4.8).   
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Figure 4.6:  Stents following two days implantation in porcine carotid arteries, viewed 
from the lumenal (inner) side. 
(A) Fluorescent microscope image of control (bare metal) stent.  Variations in light are 
caused by reflections from the uneven metal surface.  No endothelial cells are 
observed.  (B-D) Fluorescent microscope image of cell-seeded stents.  Stain: PKH26.  
(E-F) Confocal microscope image of cell-seeded stents.  Stain: PKH26.   
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Figure 4.7:  Confocal microscopy of stents following nuclear staining. 
Stains: PKH26 (red), Hoechst34580 (blue).  (A) Bare metal control stent.  (B)  pEC-
seeded stent.    
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Figure 4.8:  SEM image of stents following two days in vivo implantation. 
Examples of leukocytes are indicated by arrows.  (A) Bare metal control stent. (B) pEC-
seeded stent with confluent endothelium seen on surface.   
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4.4.8 pEC viability inside nitinol stents in vivo 
The CCK-8 metabolic assay suggested greater metabolic activity on the pEC-
seeded stent segments than on the bare metal control stent segments (p < 0.1, n = 3), 
measured by a paired test of absorbance in the medium.  Absorbance increased between 
3 hours and 21 hours and was greater than the blank condition in both the control stents 
and pEC-seeded stents.  However, the pEC-seeded stent showed a greater increase in 
absorbance than the control stent for every pair (n = 3), consistent with the hypothesis 
that pECs were covering the surface and were both viable and metabolically active 
(Figure 4.9).  
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Figure 4.9:  CCK-8 metabolic assay showing absorbance increase from 21 to 3 hours. 
Cell-seeded samples showed more metabolic activity in every pair, consistent with 
the presence of metabolically active seeded ECs.  (n = 3, cell-seeded and bare metal 
control; n = 1 blank).   
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4.5 Discussion 
Rapid endothelialization of vascular stents is highly desirable to prevent 
thrombosis and ameliorate intimal hyperplasia.  Especially in peripheral arterial disease, 
quick endothelialization may reduce the failure rates of the current standard of care.  
Ideally, stent seeding should utilize an autologous cell source so that 
immunosuppressive therapies are not required, and the cells are not immunogeneic.  
Blood-derived ECs as used in this study are an easily accessible source of autologous 
cells to each patient.  The challenge of seeding cells quickly without re-compression of 
the stent was overcome using the QuickSeedingTM methodology.   
The ex vivo results in this study show that hECs seeded onto a self-expanding 
nitinol stent with the QuickSeedingTM method remained adherent following stent 
deployment.  Cells were retained under physiological flow conditions.  Cells on the stent 
surface were functional, as demonstrated by the increase in nitrate production over 24 
hours; this increase was significantly greater after exposure of the seeded stent to flow, 
as would be expected for a healthy layer of ECs.  After QuickSeedingTM, deployment, 
and flow, there was no evidence of EC “activation” to a pro-inflammatory phenotype, as 
demonstrated by the unchanged gene levels of VCAM-1 at 24 hours.   
Antithrombotic genes COX2 and KLF-2 increased with flow but were not 
statistically significant.  The analysis was confounded by the variability introduced by 
the very small amount of RNA collected from each single stent, though housekeeping 
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gene GAPDH helped to control for this.  The coefficients of variation for KLF-2 and 
eNOS were much higher for ECs exposed to flow on the stent than on planar Ti surfaces 
[189].  Estimates of sample sizes required to evaluate the significance of COX2 and KLF-2 
expression given the current mean and standard deviation were approximately 30 and 
300, respectively.  Levels of the eNOS gene were downregulated in the flow condition, 
which is surprising since nitrate levels, indicative of NO, increased.  We have previously 
observed that nitrate levels can increase in the absence of an upregulation of the eNOS 
gene in hECs[189]; other factors such as phosphorylation of the eNOS enzyme, known to 
increase with shear stress, can increase enzyme activity and lead to more NO 
production[190-194].   
Several factors influenced the variable levels of gene expression.  Variations in 
shear stress over the stent surface likely contribute to the high variability of gene 
expression.  Computational simulations of steady-state flow over identical stent 
geometry revealed large variations in shear stress experienced by different stent surfaces 
(Chapter 3, Figure 3.4).  On lateral surfaces of the stent, a large shear stress gradient 
exists, and shear stresses vary by one order of magnitude along the width of the strut.  
Even under steady state conditions, the geometry of the stent was found to cause 
localized regions of flow reversal, equivalent to 3.6% of the fluid volume flowing 
through the stent.  This steady-state simulation closely approximates the conditions of 
our in vitro flow circuit.  The generalized collection of cells from a stent to assess gene 
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expression caused a pooling of cells from these different surfaces and introduced large 
additional variability.  Collecting cells from the stent surfaces with trypsin was difficult 
with the complex geometry, and cell collection was likely only partially complete, 
adding to variability between experiments.  Coefficients of variation for KLF-2 and 
eNOS were much higher on from the stent than from planar Ti surfaces[189].  Estimates of 
sample sizes required to evaluate the significance of COX2 and KLF-2 expression with 
these variation conditions were approximately 30 and 300, respectively.  Time-varying 
flow conditions as those occurring in vivo further increase variation in shear stress across 
stent surfaces, as presented in Chapter 3.  
Our in vivo and in vitro results demonstrate that pECs QuickSeededTM onto a 
stent just minutes before implantation remain adherent even when deployed and then 
exposed to arterial shear stresses for 24 or 48 hours.  Under these conditions, pECs 
spread on the stent surface and formed confluent monolayers.  Although shear stresses 
during deployment are not precisely known, we estimate they are below 400 dyn/cm2 
based on the expected flow rates at the vessel center.  At this level of shear stress for 15 
min exposure, we found 20% detachment after a similar static cell attachment time of 15 
min[126].  Some number of cells may be lost during deployment in the moving 
bloodstream, but sufficient cells remain to form a spread endothelial layer on the 
surface. 
 128 
The cell seeding therapy presented in this study appears safe, as no adverse 
events or outcomes were observed in any animals.  During the two-day duration of our 
in vivo studies, no gross thrombosis was observed in arteries stented with either cell-
seeded or bare metal control stents.  This was consistent with our expectations, based on 
the relatively short study duration and anticoagulant regimen (intraoperative heparin 
and daily aspirin and clopidogrel until sacrifice).   
The in vivo study was designed to establish proof of principle and a longer-term 
study is needed to evaluate any differences in surface thrombosis on stents “protected” 
by an EC covering.  Additionally, reducing the anticoagulant regimen would provide a 
greater “challenge” to the cell-seeded devices.  For the purposes of this study, the 
bilateral placement of an EC-seeded stent and a bare metal control stent in the same 
animal controlled for inter-individual differences and also increased the number of 
stents compared to the number of animals; however, the bilateral placement in this 
study design did mean that we could not collect blood to probe for any differences in 
circulating coagulation factors between animals that received an EC-seeded stent vs. a 
bare metal control stent.  In addition to thrombosis, the second major failure mode of 
stents is restenosis due to intimal hyperplasia and SMC hyperproliferation.  We 
anticipate that the paracrine factors released by ECs would help to inhibit SMC 
proliferation and intimal hyperplasia, thus addressing this mode of restenosis.  To 
properly assess intimal hyperplasia, longer-term studies are needed.   
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Explantation demonstrated endothelialization after two days on four out of four 
QuickSeededTM stents implanted in porcine carotid arteries.  In contrast, no ECs were 
observed on the bare metal control stents.  In previous porcine studies, ECs are observed 
to “mostly” cover a stent implant after 7 days[195].  Cells observed on the QuickSeededTM 
stent were the same pECs which we seeded onto the stent, and not “fall-out” cells from 
the adjacent vessel wall or circulation, as shown by the presence of the pre-implantation 
stain PKH26.  The metabolic assay performed on the explanted stents suggests that the 
adherent pECs were alive and functional after two days.  The bare metal stents showed 
metabolic activity, but to a lesser degree, consistent with the notion that both 
QuickSeededTM and bare control stents had red blood cells and other cells on the surface 
after removal from blood circulation, and that the pECs account for the greater activity 
on seeded stents.   
This study has the following limitations.  One, the seeding parameters are not 
fully optimized.  Therefore, we do not know exactly what optimal size, number, and 
spatial distribution of micropores in the delivery system wall will result in maximum EC 
coverage.  Similarly, infusion parameters such as cell concentration, infusion rate, and 
“hold time” following infusion, can be changed and may be fine-tuned for increased EC 
coverage.  Two, coverage itself is difficult to quantify; the geometry of the stent creates 
difficulty for bringing a large field into focus with conventional microscopy.  The impact 
may be that some areas of the stent are covered with a lower density of cells, which do 
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not become fully confluent when spread.  The small surface area of the stent limited the 
number of cells that could be removed and thus complicated interpretation of RT-PCR 
results.  Three, the time required to isolate and expand cells is approximately 3-4 weeks.  
Although peripheral stenting procedures are more likely to be elective when compared 
to coronary procedures, future improvements in the isolation method are needed to 
increase initial yields[196] and decrease the culture time.   
Nevertheless, this study provides an important first proof-of-concept that rapidly 
seeding ECs onto vascular stents at the point-of-care can lead to successful adhesion and 
survival after implantation.  This study avoids many of the pitfalls of previous 
approaches such as thrombogenic pre-coatings, use of non-autologous cells, and 
cumbersome manipulation of a sterile endothelialized stent back into the delivery 
catheter.  As such, the technology described here is the most clinically practical 
approach for endothelializing vascular stents that has been presented to date. 
In conclusion, we have demonstrated the feasibility of seeding autologous 
endothelial cells onto nitinol vascular stents at the point-of-care just minutes before stent 
deployment.  Stents implanted for two days into porcine carotid arteries retained seeded 
endothelium and showed no observable thrombus or safety problems.  Future studies 
should examine longer periods of implantation in vivo to further characterize the 
technology; specifically, the ability of cells to remain on the stent long-term and the 
impact of the technology on intimal hyperplasia long-term. 
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4.6 Conclusions 
We have demonstrated the feasibility of seeding autologous endothelial cells 
onto nitinol vascular stents at the point-of-care just minutes before stent deployment.  
Stents implanted for two days into porcine carotid arteries retained seeded endothelium 
and showed no observable thrombus or safety problems.  Longer term studies with 
more implantations are needed to further characterize this new technology. 
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5. Dissertation summary and future work 
5.1 Dissertation summary 
This project was motivated by the clinical need to improve the success rates of 
metal vascular stents, and reduce the incidence of thrombosis and intimal hyperplasia.  
The following hypotheses were tested:  (1) ECs seeded onto Ti blood-contacting surfaces 
minutes before implantation will create a confluent cell layer in vivo; (2) This treatment 
will prevent thrombosis when inserted into the pro-thrombotic environment of the 
inferior vena cava (IVC) in swine; (3) Fluid stress conditions on the surfaces of an 
implanted carotid artery stent are amenable to supporting endothelial cell retention and 
antithrombotic function; (4) Modification of a commercial stent delivery system with 
micropores enables rapid infusion of ECs and adhesion to nitinol stents; and (5) ECs 
remain adherent and spread to form a functional layer after stent deployment and under 
arterial fluid shear stress conditions.  The specific aims of the project were to:  (1) 
optimize seeding of ECs onto Ti tube surfaces and characterize reduction of thrombus 
formation in swine; (2) determine fluid stresses on implanted carotid artery stent and 
predict suitability of surfaces for EC seeding; and (3) evaluate adhesion and function of 
seeded ECs on stents after deployment in vitro and in vivo.   
In Chapter 2, the proof of concept was presented for using blood-derived ECs to 
cover Ti blood-contacting surfaces for reducing thrombosis in vivo.  ECs were seeded 
onto solid Ti tubes by rotating a cell suspension and tube together for 30 min, prior to 
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static culture in vitro or implantation in vivo in the porcine inferior vena cava.  All 4 cell-
seeded in vivo implants were free of clot after 3 days, whereas 4 bare metal controls 
without ECs were either entirely occluded or partially thrombosed.  Pre-labeled ECs had 
spread and were present on all 4 cell-seeded implants, while no endothelial cells were 
observed on control implants.  ECs also spread on tubes cultured statically in vitro, and 
the degree of spreading was equal to the tubes seeded and implanted in vivo.  These 
results suggest that blood-derived ECs represent a promising source of lining Ti 
implants to reduce thrombosis in vivo.  Results from Chapter 2 supported the hypotheses 
that ECs seeded onto a Ti blood-contacting surface at the point of care could spread to 
create a confluent layer in vivo, and that the EC treatment could prevent thrombosis in 
the porcine vena cava.  The results also supported progression from this materials proof 
of concept to a vascular stent application of EC seeding. 
Shear stresses and oscillatory shear indices (OSI) on various surfaces of an 
implanted carotid artery stent were calculated and presented in Chapter 3.  In both 
normotensive and hypertensive flow models, time-averaged shear stresses were <5 Pa 
on all stent surfaces.  Transient shear stresses were <27.5 Pa on all stent surfaces, and 
were highest at peak systole and on the lumenal surface.  Oscillatory shear stress was 
highest on lateral surfaces and lower lumenal surfaces.  OSI was lower in the 
hypertensive flow model on all studied surfaces, corresponding to reduced vessel 
compliance and reduced fluctuation of the input waveform.  Those regions that 
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exhibited flow reversal may alter endothelial cell function somewhat.  Results from 
Chapter 3 supported the hypothesis that fluid stress conditions on the surfaces of an 
implanted carotid artery stent are amenable to supporting endothelial cell retention and 
antithrombotic function.   
In Chapter 4, proof of concept studies for a new point-of-care EC seeding method 
of nitinol vascular stents were presented.  Stent delivery systems which had been 
modified with small micropores allowed for the delivery of a cell suspension by 
infusion, so that ECs could be introduced to a stent minutes before its deployment in 
vitro or in vivo.  ECs adhered to the stent, with coverage of 55,000 ± 9,500 cells/cm2.  ECs 
spread to c over the surface, following 24 hours culture in vitro under static or flow 
conditions.  After flow, ECs exhibited increased production of the antithrombotic 
vasodilator nitric oxide.  Additionally, after 24 hours flow, expression of genes KLF-2 
and COX2 trended upward from their static baseline.  After 48 hours in vivo, rapidly-
seeded autologous ECs had spread to cover the surfaces of stents deployed in porcine 
carotid arteries (n = 4).  A cell metabolism assay showed that EC-seeded stents had 
higher levels of cell metabolism after implantation, a difference which is attributed to the 
ECs on the surface and supports the idea that seeded ECs remained alive and functional 
in vivo.  The results presented in Chapter 4 supported the hypotheses that modification 
of a commercial stent delivery system with micropores enables rapid infusion of ECs 
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and EC adhesion to nitinol stents, and that ECs remain adherent and spread to form a 
functional layer after stent deployment and under arterial fluid shear stress conditions. 
Overall the results presented in this dissertation support the feasibility of a point-
of-care method for stent seeding.  Specifically, we found that ECs seeded onto Ti 
surfaces and nitinol stents minutes before introduction into the arterial or venous 
bloodstream in vivo remained adherent and spread to form a functional endothelial 
layer.  We found that ECs seeded onto stents and exposed to steady flow in vitro 
released nitric oxide and expressed some of the anti-thrombotic genes typically 
upregulated under flow conditions.  We also found that fluid shear stresses on the 
surface of a commercial nitinol stent implanted in a carotid artery are conducive to 
supporting EC adhesion and function, using a computational fluid dynamics model. 
5.2 Future work to complete current studies 
In Chapter 3, the shear stresses and oscillatory shear stresses on a deployed stent 
were determined and presented.  Other commercial stent designs and other vessel sizes 
could be modeled to further expand and complete this study.  Additionally, the shear 
stresses on the stent during deployment were not determined, but are expected to be 
non-negligible.  Evaluating stent deployment in bloodflow as a moving boundary 
problem would give insight to the expected portion of cells lost during in vivo stent 
expansion to further complete this study. 
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In Chapter 4, feasibility studies for a point-of-care stent endothelialization 
method were presented.  Input parameters for seeding could be further optimized, 
including: (1) cell infusion rate, (2) cell suspension concentration and volume, (3) size 
and distribution of micropores, and (4) “hold” time between cell infusion and stent 
deployment.  These parameters were established for feasibility studies without 
systematic optimization, which could enhance cell coverage for subsequent studies.  
Additionally, pre-coating of the stent with an antibody or protein to enhance cell 
attachment remains as an option, though it would complicate the method concept. 
To further complete the work presented in Chapter 4, longer term in vivo  studies 
are recommended.  A longer study duration is needed to assess the impact of EC 
seeding on thrombosis and intimal hyperplasia (with histological analysis).  At a later 
time point, the initial inflammation from the stenting procedure would be reduced, 
allowing for better assessment of any sustained innate immunity response and leukocyte 
attachment to stents, as was observed in the short-term study of Chapter 4.  While the 
studies in Chapter 2 presented strong differences in coagulation following EC seeding, 
these studies were conducted in the low-shear environment of the inferior vena cava.  To 
assess effectiveness of the EC stent seeding on reducing surface thrombosis, a longer 
study is needed in the high-shear arterial implantation site.   
To quantitatively assess the in vivo coverage with seeded ECs on implanted 
stents, a non-destructive visualization method would be required.  We have proposed 
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an internal visualization device based on an endoscope platform with added fluorescent 
capability.  Further work to develop this device to a working state would allow 
assessment of EC coverage to further complete the studies in Chapter 4. 
5.3 Implications of this research 
This work represents the first introduction of a point-of-care method for 
endothelializing metal stents with autologous cells.  As discussed in Chapter 1, almost 1 
million stents are placed each year in the United States alone, when considering both 
coronary and peripheral stenting procedures.  These stents have the potential to fail 
because of thrombosis and intimal hyperplasia, and up to one quarter of these will 
require re-intervention, depending on the stent location and type (bare vs. drug-eluting).  
A new method and technology with the potential to improve restenosis rates could 
translate to years of improved patient quality of life, as well as reduced hospital costs 
because of a potentially reduced number of required re-interventions.  
Results from Chapter 2 illustrate that autologous blood-derived ECs covering a 
Ti surface in contact with the bloodstream can prevent thrombosis at the metal surface.  
Application of this result to VADs, as mentioned in Chapter 1, or to stents, as we did in 
Chapter 4, has the potential to reduce embolic events with VADs and improve restenosis 
outcomes of stents, respectively.  Further, the covering of a metal implant surface with 
ECs to prevent coagulation could reduce the need for long-term preventative 
anticoagulation therapy for patients with these implants.  Because such therapies have 
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high risk of bleeding complications and sometimes require routine blood testing, a 
technology that could reduce the use of these anticoagulants without requiring 
immunosuppression could be very beneficial to these implant patients, and ultimately 
reduce medical costs. 
In Chapter 3, our results indicated that shear stresses on a stent implanted into 
the carotid artery were likely conducive to the retention and desirable function of ECs 
seeded onto the surface.  This study was the first to closely examine shear stresses or 
oscillatory shear index on the surfaces of the stent itself, and supports the feasibility of 
point-of-care stent seeding for both normotensive and hypertensive conditions.  If a cell 
seeding therapy is proposed for clinical implementation in the future, such models 
would help to support feasibility and effectiveness claims.  Examining fluid impacts on 
the surfaces of stent struts could also help to inform and direct design of a stent that may 
be prospectively and intentionally designed for point-of-care endothelialization.  As 
others in the past have shown that stent geometry impacts shear stress on the 
intermediate vessel wall between struts, it is also expected that geometry would impact 
shear stresses on the surface of the stent itself.  Modeling shear stresses on a stent surface 
for different potential geometries and designs represents a more efficient development 
strategy than testing a wide variety of stent designs with ECs experimentally. 
Our results in Chapter 4 show the proof-of-concept of seeding ECs onto stents 
just ten minutes before the stents are deployed into the arterial bloodstream.  Although 
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the ECs had a limited time to attach to the surface, and although the surface was 
untreated with any protein or substance to enhance adhesion, ECs were retained after 
deployment in vivo and spread to cover the surface after 2 days.  Such a result may be 
surprising to those not familiar with our previous work with ECs and Ti, and represents 
a strategy for endothelializing stents with potential for clinical application.  As described 
in Chapter 1, past work to seed stents with endothelium has been hampered by cell 
source, long culture times of stent and cells together, and the difficulty of manipulating 
stents back into a delivery catheter while maintaining sterility, and without loss of the 
endothelial layer.  Balloon expandable stents suffered from large losses of pre-cultured 
cells on the lumenal surface after the abrasion of the balloon against the stent required 
for stent expansion.  In contrast to those past studies, the work in Chapter 4 is more 
practical for clinical implementation.  An individual’s cells could be collected as 
described, and the stent and delivery system with micropore modifications for infusion 
could be used “off the shelf.”   
In total, the results in this dissertation suggest that point-of-care seeding of 
titanium blood-contacting surfaces with blood-derived ECs is both feasible and effective 
for preventing thrombosis. 
5.4 Future directions for the point-of-care stent seeding project 
This project was intended to investigate the feasibility of a point-of-care method 
for endothelializing nitinol stents and titanium cardiovascular implants with autologous 
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cells.  While the results within this dissertation are promising as a first proof of concept, 
there are multiple directions in which the project could go to develop a clinically feasible 
strategy for point-of-care endothelialization of stents.  Future work should first focus on 
(1) improving coverage of the stent after seeding, (2) long-term studies in vivo, and (3) 
improving the efficiency of EC isolation from blood, in order to shorten the time 
between initial blood draw and stent seeding.  Finally, adoption of the technology to 
clinical use will also require attention to logistical details of the procedure and the 
connection between cell technician and clinician. 
Improving coverage of the stent after seeding may be partly accomplished by 
optimizing seeding parameters as described above.  Cell concentration, infusion rate, 
and “hold time” may all contribute to differences in EC coverage on deployed stents.  
User factors such as speed of sheath retraction during deployment may also impact cell 
retention.  More involved methods for improving stent coverage may include 
technologies such as brief inflation of a proximal occlusion balloon during stent 
deployment to temporarily halt blood-flow and thus reduce the fluid shear stress from 
flowing blood experienced by the stent during deployment.  Temporary occlusion has 
been suggested previously for local cell delivery to a magnetized stent[72]; the duration of 
occlusion required to accomplish stent deployment would be much less than the 5-10 
min proposed in that study to deliver cells. 
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Long-term studies in vivo were described above as future work to complete the 
current studies.  In order to translate the point-of-care stent seeding method to clinical 
practice, long-term animal studies with larger numbers of subjects will be required to 
support any application for first human use.  In addition to establishing safety, such 
studies will investigate and establish the effectiveness of the proposed seeding method 
in reducing thrombosis and intimal hyperplasia.   
To reduce the lead time between drawing blood to isolate ECs and the stenting 
procedure, it would be necessary to improve the efficiency of EC isolation from blood.  
We have proposed and begun to investigate methods to isolate ECs at the point-of-care.  
With sufficiently specific antibodies or capture molecules, circulating endothelial 
progenitor cells could be collected from blood in a procedure similar to apheresis.  It is 
likely that the total numbers of ECs collected would still be less than the number 
obtained after isolation of a few colonies and subsequent multiple weeks culture in vitro.  
Therefore, point-of-care EC isolation would need to be married with the increase in 
seeding efficiency to be practical. 
Finally, challenges exist to adoption of this endothelialization technology in 
clinical use.  As described in this dissertation, preparation of the cell suspension is done 
in a laboratory environment using a sterile biological hood and other equipment such as 
a centrifuge.  If the technology is applied using cells expanded in a laboratory culture 
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facility (vs. those isolated at the point-of-care), coordination between the culture facility 
and operating suite will be important, as well as close proximity between the spaces.   
Adoption by clinicians will be an important piece of this roll-out, as the 
preparation of the stent delivery system and infusion of the cell suspension is closely 
tied to the timing of pre-stenting balloon angioplasty and the stent deployment itself.  
While the delivery system preparation and infusion of the cell suspension could be 
accomplished by ancillary personnel in the sterile field, it is unknown at this point how 
critical the timing of cell infusion is, or what consequences may result from completing 
the infusion too early and allowing the seeded stent to sit for an extended time.  
Clinicians may be resistant to the additional time of the cell infusion, if required to wait 
for it to finish in order to proceed with the stenting procedure.  Still, similar hurdles in 
training and practice have been overcome previously, such as compression of 
endovascular heart valves by clinicians onto a delivery system at the point of care. 
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Appendix A: Protocols specific to this work 
A.1  Protocol for Titanium Tube Seeding 
Supplies/Equipment: 
-Rotating Seeding Motor 
-Cells (recommend 2xT150 or 4xT75 to have enough to seed and replate) 
-Trypsin 
-TNS 
-DPBS (-/-) 
-Cell Tracker Orange (CTO) 
-Serum Free Medium – EBM-2+EGM-2 
-Serum Medium – EGM-2+EGM-2+2% PS (for pEPC) or 10% FBS (for CBEPC) 
 
Sterile Checklist: 
-Sterile gloves x 3 or more pairs 
-Black “Luer-Lok Tip cap” 
-Sterile field towels (2) 
-Reservoir [100 mL polycarbonate Erlenmeyer flask] 
-Pulse Dampener with Large Inlet/Outlet Connections 
-Silastic Tubing ½” diameter, approx.  18-22 inches in length 
-Silastic Tubing ½” diameter, approx. 3 cm in length X2, TWO SECTIONS 
-Silastic Tubing ½” diameter, approx. 5-6 cm in length 
-Titanium machined inlet & outlet adapters 
-COBE 3/8” x 3/32” SMARxT tubing, 5 foot long section (gas sterilize only) 
-COBE 3/8” x 3/32” SMARxT tubing, 5-6 cm long section (gas sterilize only) 
-3/8” to ½” adapter (gas sterilize only) 
 
For seeding 5/8” Ti Tubing: 
-10 mL syringe 
-Assembled Titanium tube 
-Cut 10 mL syringe (recommend cut at ~1.5 mL mark) 
-2 sections of “large” Silastic tubing approx.  2-3 cm in length 
 
For seeding ½” Ti Tubing: 
-5 mL syringe 
-Assembled Titanium tube 
-Cut 5 mL syringe (recommend cut at 0.8mL mark) 
-2 sections of “medium” Silastic tubing approx.  2-3 cm in length 
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Other Supplies: 
-Lab tape & timer 
-Hemacytometer 
 
A. Cell Tracker Staining [written for use with Cell Tracker Orange – could use other] 
1. To make CTO 1mM stock solution, thaw vial of 50mg aliquot in light-protected 
container in hood and add 90 uL of sterile DMSO to vial.  
2. For CTO already made, thaw CTO to room temperature by placing under hood 
in light-protected conical tube.   
3. Warm up serum free medium (DMEM-F12+Antibiotic/Antimycotic) and DPBS(-
/-) (without Calcium & Magnesium) 
4. Turn off fluorescent light in hood 
5. Aspirate regular medium off of cells 
6. Rinse cells twice with DPBS (-/-)  
Note:  approx. 30 sec. each rinse; 6 mL will cover T-75 and 12 mL will 
cover T-150.  Place DPBS (-/-) back into heat bath; will use again. 
7. To prepare CTO staining medium, aliquot 6mL serum free media for each T-75 
and 12 mL for each T-150 flask to be stained. 
8. Add 2 uL CTO solution per 1mL of serum free medium to be used.   
Note: Serum free media is needed because serum media would 
cleave/interfere with CTO 
9. Add specified volume media with CTO to cells and incubate at 37*C for 15 
minutes 
 
B.  Seeding Chamber Assembly 
1. While CTO is incubating with cells, use the available time to assemble the 
chamber for seeding of titanium tube.  Fluorescent light may be on for these 
steps. 
2. Lay out sterile field towel in one side of hood (recommend opposite from the 
vacuum)  
3. Place the following sterile supplies onto sterile field: 
a. 10 mL syringe 
b. Assembled Titanium tube 
c. Cut 10 mL syringe (recommend cut at ~1.5 mL mark) 
d. 2 sections of Silastic tubing approx.  2-3 cm in length 
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e. Black “Luer-Lok Tip cap”  
4. With sterile gloves, carefully push one piece of Silastic tubing onto each end of 
Titanium tube assembly.   
Note: Silastic tubing should be advanced onto Ti tube as far as it may 
easily go, and must be pushed past the beginning of the shrink tube 
holding Ti tube assembly together – otherwise cell solution will leak out 
between sections of Ti! 
5. Push the cut 10 mL syringe, cut end first, into one of the open pieces of Silastic 
tubing, as far as it will go. (this should be able to be fully against Ti tube) 
Note:  If there is a concern about temperature of tube, the entire assembly 
may be placed in a sterile screw-top container in incubator until just 
before cells are inserted. 
6. The last step that may be done to prep the seeding chamber is to remove the 
plunger from the 10 mL syringe and set both pieces back in the field, (need to 
keep both), then add the syringe cap to the Luer end of the syringe. 
7. Also while cells are staining with CTO, place rotating motor device into 
incubator where desired; it is not necessary to plug it in at this time. 
 
C. Passaging and Cell Seeding 
1.  While cells are incubating with CTO, warm trypsin (.025%) and TNS aliquots (4 
mL trypsin/T-75 and 8mL TNS/T-75). 
2. Prepare other equipment – clean hemacytometer & coverslip as well as P20 pipet 
and place in hood. 
3. When 15 minute incubation of cells with CTO is complete, turn off fluorescent 
hood light and retrieve cells. 
4. Aspirate off media with CTO and rinse cells twice with DPBS (-/-) 
Note:  approx. 30 sec. each rinse; 6 mL will cover T-75 and 12 mL will 
cover T-150.  DPBS is done with use after this. 
5. Add trypsin to cells in volumes stated above; Place flask in incubator for 3 
minutes. 
6. At 3 minutes, take flasks out and knock against bench.  Look at cells under 
microscope to be sure that cells are detached and floating; if they are not, allow 
to incubate for another minute or so. 
7. In hood, quickly add appropriate volumes of TNS to each flask. 
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8. Pipet the trypsin/TNS solution up and down and each flask and squirt it against 
the bottom surface of the flask a few times to detach any remaining adherent 
cells. 
9. Pipet all solution in each flask up and place into conical tube for centrifuge. 
10. Pipet solution up and down quickly to mix and then squirt 10uL of cell solution 
into one side of hemacytometer, change pipet tip, and repeat for the other side of 
hemacytometer. 
11. Check volume of solution in conical tube for use in cell count, and then 
centrifuge cells (1400 RPM, 5 minutes) with appropriate counterbalance. 
12. While cells are spinning, complete cell count as follows: 
a. Count one side (4 sets of 4x4 boxes) then count the other side.  Add all 
together and divide by 8, multiply by 10000, then multiply by volume of 
liquid (mL) in the conical tube.  This is the number of cells in conical. 
13. When centrifuge cycle is over, remove cells and counterbalance from centrifuge, 
being careful not to disturb pellet at bottom of conical  
Note: Cells are still stained with CTO so be conscious to protect cells from 
excess light when reasonably possible. 
14. In hood, gently aspirate supernatant solution by tilting the tube and aspirating 
liquid, not disturbing cell pellet. 
15. Based on cell count, add appropriate amount of serum free medium (DMEM-
F12+A/A) to reach desired cell concentration.  Pipet up and down to mix cells 
well into suspension. 
Note: typical seeding density has been 1M/mL.  Minimum volume 
needed is 9-10 mL; do not resuspend in smaller volume than that even if 
cell count is lower. 
16. Pipet 9-10 mL of cell suspension into open syringe barrel with cap attached.  
Leave any remainder of cell suspension for replating a few steps later. 
17. Insert plunger back into open end of syringe as far as possible 
Note: if possible, gently push plunger until it passes a ridge and snaps 
back into place – it is easier to do this while capped to avoid squirting out 
cell solution. 
18. Invert syringe so that luer end points up and remove black cap.  Carefully 
advance syringe past the ‘snap ridge’ if not done already, being careful to control 
plunger and avoid squirting cell solution everywhere.  It is not 
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necessary/recommended to advance plunger and solution all the way to opening 
at this time. 
19. Insert syringe luer end first into other open end of Silastic tubing attached to the 
titanium tube assembly.  Advance syringe as far as it can go into Silastic tube to 
minimize volume needed to fill seeding chamber. 
20. Onc e syringe is fully in place, hold assembly with open end of cut syringe up 
and slowly advance plunger with cell solution until cell solution can be seen 
coming into cut syringe.  Continue advancing plunger until cell solution forms a 
nice bead at top, and add black cap on top of bead, so that no bubbles should be 
inside tube assembly. 
21. Place sterile glove(s) inside hood and carefully insert tube/syringe assembly into 
inside of one glove and down one of the fingers.  Use lab tape or rubber bands to 
close off glove at open cuff end, enclosing assembly inside. 
Note: this is done to maintain sterility of entire assembly while seeding in 
incubator. 
22. Remove assembly in glove from hood and insert into prongs of rotating motor 
device (for 0.625” size) or fasten into syringe holder (for 0.500” size) in incubator, 
with the black cap end first and the lightweight syringe plunger end sticking out. 
Note: One shelf is in incubator for this step, and one should be out of the 
incubator, available for assembly of flow circuit if applicable. 
23. Check to see that titanium tube is as level as possible by eye or using a level, and 
adjust if necessary by placing small items under either end of rotator. 
24. Situate cord in incubator door and tape if necessary; plug in motor device and 
quickly observe to ensure that device is indeed rotating.  Set timer to 30 minutes 
and start timer. 
25. Return to hood to use remainder of cell suspension.  Fluorescent light in hood 
may be turned on at this point. 
26. Based on remaining volume of cell suspension, decide how many flasks to 
replate and prepare those flasks with appropriate volume of growth medium. 
Note: Growth medium used has been EBM-2+SQ+2%PS.  Plate 13 mL 
medium into each T-75 and 25 mL into T-150. 
27. Use P-1000 pipet to insert desired number of cells (1M/mL) into each flask.  
Gently slide flask on hood surface in Figure “8” pattern to evenly distribute cells 
in flask.  Close flasks and return to incubator.   
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A.2  Protocol for Titanium Tube Culture in Flow 
Assembly / Preparation of Large Flow Circuit for Large Stockert-Shiley Roller pump 
1. While cells are seeding in rotational device, as much preparation of flow circuit as 
possible should be completed. 
2. It is recommended to remove any unnecessary items from hood and remove sterile 
towel that was used for assembly of seeding chamber and lay out a new [large] 
sterile field towel on one side of hood for assembly of flow circuit. 
3. Carefully place the following sterile supplies onto sterile field: 
a. Reservoir [100 mL polycarbonate Erlenmeyer flask] 
b. Pulse Dampener with Large Inlet/Outlet Connections 
c. Silastic Tubing ½” diameter, approx.  18-22 inches in length 
d. Silastic Tubing ½” diameter, approx. 3 cm in length X2, TWO SECTIONS 
e. Silastic Tubing ½” diameter, approx. 5-6 cm in length 
f. Titanium machined inlet & outlet adapters 
a. COBE 3/8” x 3/32” SMARxT tubing, 5 foot long section (gas sterilize only) 
g. COBE 3/8” x 3/32” SMARxT tubing, 5-6 cm long section (gas sterilize only) 
h. 3/8” to ½” adapter (gas sterilize only) 
4. Spray down extra incubator shelf well and wipe off with Kimwipe, placing the 
incubator shelf into the hood next to sterile field towel.  Orient shelf as it would sit in 
the incubator, with upturned lip out toward hood opening, and downturned lip in 
back of hood. 
5. Complete steps 6-15, flow circuit assembly, with sterile gloves. 
6. Place reservoir upright on front right corner of incubator shelf and securely tape in 
place with LOTS of lab tape.   
7. Connect one end of 5’ long 3/8” SMARxT tubing to pulse dampener; the other end 
may be placed in the reservoir to keep it out of the way if desired.   
8. Connect the other end of pulse dampener to short (5-6cm) piece of SMARxT tubing. 
9. Connect the open end of short SMARxT tubing to 3/8” to ½” adapter. 
10. Connect the open end of 3/8” to ½” adapter to 5-6 cm long Silastic tubing. 
11. Connect the open end of Silastic tubing to small/entry end of titanium inlet adapter. 
12. Connect open end of titanium inlet adapter to 3 cm Silastic tubing.   
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Note: Tubing hanging off of titanium adapter should be short enough that 
you will be able to push it fully over tube with cells to fully abut the two 
pieces together; if tube looks too long, trim it now with sterile razor/scalpel. 
13. Lay titanium inlet piece aside on sterile field. 
14. Connect large end of titanium outlet adapter to the other 3 cm Silastic tubing. 
Note: Again, tubing hanging off of titanium adapter should be short enough 
that you will be able to push it fully over tube with cells to fully abut the two 
pieces together; if tube looks too long, trim it now with sterile razor/scalpel. 
15. Connect small open end of titanium outlet adapter to the long Silastic tubing; the 
other end of Silastic tubing may be placed in the reservoir to keep it out of the way if 
desired.  Lay open end of titanium outlet adapter aside on sterile field. 
16. I recommend marking arrow(s) on the long section of 3/8” SMARxT tubing to show 
the direction of flow, from the reservoir forward to the pulse dampener.  It is hard to 
tell which end is which when tubing is pushed through the small hole in incubator, 
and this will get the direction of flow correct. 
17. Use zip ties and zip tie gun to snugly apply a total of 4 zip ties to secure circuit as 
follows: 
a. Tie Silastic tubing at both ends of titanium inlet adapter 
b. Tie Silastic tubing at both ends of titanium outlet adapter 
 
 
Figure 1.  Suggested configuration for large flow circuit in incubator. 
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18. When the 30 minutes is up and it is time for the titanium tube to come out of the 
seeding device, remove the assembly in the glove from the prongs and remove the 
seeding device and its shelf from incubator, if flow circuit is to be placed in same 
space.  Unplug rotating device. 
19. Take glove and tube assembly back into hood and undo or cut tie from cuff end of 
glove, removing titanium & syringe assembly into sterile field. 
20. Remove Silastic tubing from both ends of titanium tube containing cells, being 
careful not to scrape inner surface of titanium with inserted syringe other anything 
else. 
a. Note: If desired it is possible to uncap cut syringe first and withdraw liquid 
slowly into full syringe, to minimize mess.  This should be done slowly to 
avoid detaching cells on titanium tube. 
21. The next steps should be completed carefully but quickly to avoid the cells drying 
out; Insert the open Silastic tubes on titanium adapters over both ends of the 
titanium tube containing the cells.  As when assembling the seeding chamber, the 
Silastic tubing must be pushed on far enough to be over shrink tubing and avoid 
leakage of fluid through tube. 
22. When circuit is fully assembled and sealed off, hold the open ends of circuit that will 
go in the reservoir upright and quickly begin filling the circuit with serum medium 
(DMEM-F12+2%PS+A/A) by carefully and slowly pouring medium into the Silastic 
tubing (as this is the largest and easiest to pour into). 
23. Try to fill the pulse dampener as desired so that the liquid level is a bit above the 
inlet and outlet and move the long tubing around to work any bubbles in the tubes 
up the open ends of the tubing, so that no large bubbles are in the circuit.  Continue 
filling tubes with medium within 1-2 cm of the open ends. 
24. Quickly (to avoid spilling) insert the open tubing ends into the open mouth of the 
reservoir.  Tubing fits closely in the reservoir mouth; remember that the 3/8” 
SMARxT tubing is the inlet and should be pushed further down into the reservoir 
than the ½” Silastic outlet tubing. 
25. Some liquid will flow from the tubes into the reservoir, leaving empty gaps in the 
tubing.  This is acceptable because when the flow begins, bubbles before the sample 
will go to the bubble trap / pulse dampener, and bubbles after the sample will be 
pushed back to reservoir. 
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26. With a 25 mL pipet, fill the reservoir to just below the level where the threads for the 
cap begin.  This will look very full, but some of this volume will fill the spaces that 
just formed in the tubing. 
Note: The volume of medium required to fill the circuit and reservoir has 
been approximately 400 mL in my experience (3 setups) 
27. If you have not already done so, tape the pulse dampener, adapters, and sample into 
place on the incubator shelf so that they will not come apart and fall over when 
placed into the incubator.  Place the long section of 3/8” SMARxT tubing on top so 
that it is easy to access to insert into pump. 
28. Remove shelf and attached flow circuit carefully from the hood and carefully carry 
to incubator.  Place shelf into incubator and make one fold in 3/8” tubing to push it 
through the hole in the incubator wall.   
29. Push or pull through as much of the 3/8” tubing as possible without displacing the 
other circuit components. 
30. If all components are stable, close the incubator door and move to the large pump. 
31. ENSURE THE PUMP IS SWITCHED OFF and open the cover above the roller. 
32. Open both tubing clamps and identify the end of the tubing that is the inlet (from 
your previous marks on the tubing).  Lay this end into the first tubing clamp (at 
bottom) and secure tubing.   
Note: Pump is currently set up to rotate counter-clockwise.  Inlet should be 
the bottom end. 
33. Roll the pump by hand around onto tubing, laying tubing in between the white 
guides. 
34. When tubing is fully in the “raceway,” push the free end of tubing so that sits tightly 
against the curved wall of the pump and secure that outlet end of tubing in the top 
tubing clamps. 
35. Close the cover and ensure that the pump speed is set to zero. 
36. Turn on pump and switch the dial from zero to counter-clockwise flow.   
37. Turn the pump up to a fraction of the desired experimental flow; flow should be 
ramped up over a period of approximately 15 minutes, in about 4 increments. 
38. Look at the flow circuit in the incubator and ensure that there are no leaks.  The 
bubbles in the tubes may remain stationary until higher flow rates (1LPM) are 
reached, when they will be pushed into the bubble traps. 
39. If the pulse dampener level is not sufficient, hold it so that a little bit more liquid 
goes into it and then lay it down flat again. 
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40. Tape to the shelf again any components that seem unstable. 
41. Continue ramping the flow to the desired level over the first 15 minutes and make a 
note of the time zero of the experiment.  Clean up the hood and you are done! 
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A.3 Protocol for Titanium Tube Tube seeding for Surgical 
Implant 
Supplies/Equipment: 
-Rotating Seeding Motor 10 RPH – In O.R. 
-Machined holder to connect tube to Motor – Attached to motor in O.R. 
-Incubator for Seeding/Rotation – In O.R. 
-Cells (recommend 3xT75 confluent to have enough to seed) 
-Trypsin (.025%) (4 mL each T-75) 
-TNS Trypsin Neutralizing Solution (8 mL each T-75) 
-DPBS (-/-) 
-PKH26 kit for fluorescent labeling 
-Serum (PS or FBS )to use with PKH26 kit (3 mL for each T75) 
-Serum Free Medium – EBM-2+EGM-2 
-Serum Medium – EGM-2+EGM-2+2% PS (for pEPC)  
 
Clean/Sterile Checklist: 
-Sterile gloves x 3 or more pairs 
-Black “Luer-Lok Tip cap” 
-Sterile field towels (2) 
-5 mL syringe 
-Assembled Titanium tube, enough for control and cell use 
-Cut 5 mL syringe (recommend cut at 0.8mL mark) 
-2 sections of “medium” Silastic tubing ½” diameter, approx.  3-4 cm in length 
 
Other Supplies: 
-Lab tape & timer 
-Hemacytometer 
 
A.  PKH26 Staining – Long-term membrane dye kit from Sigma; protocol approximates 
kit instructions. 
 
Note:  The morning that surgery is scheduled, complete the PKH26 staining in advance, 
then the cells will be placed back in normal medium until it is time to passage them. 
1. Wash/rinse cells in serum free media 2 times (for about a minute each). 
a. 4 mL each T75; 4x3x2 = 24 mL to warm 
2. Per the PKH26 kit protocol, mix the PKH26 red dye and the “Diluent C” 
component  in a 15 mL conical, to a concentration of 4uM: 
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a. 3 mL of mixture is needed for each T75; Total is 9 mL Diluent C and 
36 uL of dye.   
3. Gently invert the capped conical to mix, then add 3 mL of dye mixture to 
each T75. 
4. Allow the dye mixture to incubate flat on the cells in the hood at room 
temperature, 4 minutes. 
5. After 4 minutes, stop the reaction with an equal volume of serum(FBS or PS). 
a. 3 mL each T-75 for 9 mL total to warm up 
6. After 1 minute, dilute this with full medium 1:1.  Add a total of 6 mL full 
medium to each T75 (6x3 = 18 mL to warm up) 
7. Aspirate all liquid from cells and wash 2x, possibly 3x, with full medium. 
a. 4 mL each T75 x 3 x 2 = 24 mL to warm up 
8. Cover each T75 with a normal volume of full medium and return flasks to 
incubator, away from light, until it is time to start passaging. 
a. 13-15 mL each T75 x 3 = 45 mL to warm up. 
 
B.  Seeding Chamber Assembly 
1. Lay out sterile field towel in one side of hood (recommend opposite from the 
vacuum)  
2. Place the following sterile supplies onto sterile field: 
a. 5 mL syringe 
b. Assembled Titanium tube, including: 
A. Cut 5 mL syringe (recommend cut at ~0.8 mL mark) 
B. 2 sections of Silastic tubing approx.  3-4 cm in length 
c. Black “Luer-Lok Tip cap”  
3. The last step that may be done to prep the seeding chamber is to remove the 
plunger from the 5 mL syringe and set both pieces back in the field, (need to 
keep both), then add the syringe cap to the Luer end of the syringe. 
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Figure 1.  Assembled titanium tube system, shown here with yellow syringe cap instead 
of black pointed cap. 
 
C. Passaging and Cell Seeding 
1. Prepare other equipment – clean hemacytometer & coverslip as well as P20 
pipet and place in hood. 
2. When the go-ahead for cell seeding is given from the OR team, proceed to 
step 3. 
3. Aspirate off media from T75s and rinse cells twice with DPBS (-/-) 
Note:  approx. 30-60 sec. each rinse; DPBS is done with use after this. 
4. Add trypsin to cells (4mL ea T75); Place flask in incubator for 3 minutes. 
5. At 3 minutes, take flasks out and knock against bench.  Look at cells under 
microscope to be sure that cells are detached and floating; if they are not, 
allow to incubate for another minute or so. 
6. In hood, quickly add appropriate volumes of TNS (8mL ea T75) to each flask. 
7. Pipet the trypsin/TNS solution up and down and each flask and squirt it 
against the bottom surface of the flask a few times to detach any remaining 
adherent cells. 
8. Pipet all solution in each flask up and place all together into one conical tube 
for centrifuge. 
9. Pipet solution up and down quickly to mix and then squirt 10uL of cell 
solution into one side of hemacytometer, change pipet tip, and repeat for the 
other side of hemacytometer. 
10. Check volume of solution in conical tube for use in cell count, and then 
centrifuge cells (1400 RPM, 5 minutes) with appropriate counterbalance. 
11. While cells are spinning, complete cell count as follows: 
a. Count one side (4 sets of 4x4 boxes) then count the other side.  Add all 
together and divide by 8, multiply by 10000, then multiply by volume 
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of liquid (mL) in the conical tube.  This is the number of cells in 
conical. 
12. When centrifuge cycle is over, remove cells and counterbalance from 
centrifuge, being careful not to disturb pellet at bottom of conical tube.  
Note: Cells are still stained with PKH so be conscious to protect cells from 
excess light when possible.  Cell pellet should be a bright red-orange. 
13. In hood, gently aspirate supernatant solution by tilting the tube and 
aspirating liquid, not disturbing cell pellet. 
14. Based on cell count, add appropriate amount of serum free medium (DMEM-
F12+A/A) to reach desired cell concentration.  Pipet up and down to mix cells 
well into suspension. 
Note: typical seeding density has been 2-2.5M/mL.  Minimum volume 
needed to fill chamber is 4.5 mL; do not resuspend in smaller volume 
than that even if cell count is lower.  Be sure to record cell count and 
seeding density! 
15. Pipet 4.5-5 mL of cell suspension into open syringe barrel with cap attached.   
16. Insert plunger back into open end of syringe as far as possible.  Note that the 
device should be only be handled with sterile gloves – 2 people may make 
this pipetting/assembly step easier. 
Note: if possible, gently push plunger until it passes a ridge and snaps 
back into place – it is easier to do this while capped to avoid squirting out 
cell solution. 
17. Invert syringe so that luer end points up and remove black cap.  Carefully 
advance syringe past the ‘snap ridge’ if not done already, being careful to 
control plunger and avoid squirting cell solution everywhere.  It is not 
necessary/recommended to advance plunger and solution all the way to 
opening at this time. 
18. Insert syringe luer end first into the open end of Silastic tubing attached to 
the titanium tube assembly.  Advance syringe into Silastic tube, but not past 
the edge of the Titanium tube; this would displace cells from the space over 
the end of the tube. 
19. Onc e syringe is fully in place, hold assembly with open end of cut syringe up 
and slowly advance plunger with cell solution until cell solution can be seen 
coming into cut syringe.  Continue advancing plunger until cell solution 
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forms a nice bead at top, and add black cap on top of bead, so that no bubbles 
should be inside tube assembly. 
20. Place sterile glove(s) inside hood and carefully insert tube/syringe assembly 
into inside of one glove and loosely down one of the fingers.  Use lab tape or 
rubber bands to close off glove at open cuff end, enclosing assembly inside. 
Note: this is done to maintain sterility of entire assembly while 
transporting and seeding in incubator. 
21. Remove assembly in glove from hood and quickly carry entire assembly to 
OR at Vivarium.  It is advisable to continuously gently move or rotate the 
tube while it is being carried to the OR. 
22. In the OR, insert into syringe holder in incubator and screw the syringe 
holder closed, with the black cap end first and the lightweight syringe 
plunger end sticking out. 
23. Check to see that titanium tube is as level as possible, using a level, and 
adjust if necessary by turning knobs on motor holding apparatus. 
 
Figure 2.  Titanium tube and motor assembly, pictured here without sterile glove 
covering. 
 
24. Situate cord in incubator door and tape if necessary; plug in motor device 
and observe to ensure that device is indeed rotating.  Set timer to 30 minutes 
and start timer.  
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25. At the end of the 30 minutes, as long as the OR Surgical team is ready, 
remove the syringe assembly from the syringe holder and carefully release 
the lab tape or rubber band holding the sterile glove closed.   
26. WITHOUT TOUCHING THE INSIDE of the glove or the sterile surgical field, 
ease the syringe assembly out and present it to the surgical team.   
27. The surgical team should remove the Silastic ends from the tube and quickly 
prepare the tube for implantation.  It is helpful to keep the implantation field 
hydrated with saline while the implant is sutured into place. 
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A.4  Protocol for Titanium Tube Cleaning 
Cleaning Protocol: Ti Tubing 
1. Clean Ti tube with Alconox soap solution and soft sponge, rinse many times with 
DI H2O 
2. Submerge Ti pieces in Aqua Regia in very clean glass petri dishes for 5 minutes. 
(NOTE: THIS PART IS VERY DANGEROUS) 
Petri dishes must be very clean, usually clean as step 1 
3. Submerge Ti pieces in DI H2O to clean off Aqua Regia (approximately 1 L of H2O 
per 21 pieces) and then rinse very thoroughly with a few more liters of DI H2O 
4. Proceed to next steps for soap and water sonication. 
 
Cleaning Protocol: Plastic Parts, Flexible Tubing, Ti tubing Part II 
1. Sonicate in Kendal sonicator for 2 cycles of 480 seconds in 1:1 Alconox, DI H2O 
solution (use a Ziploc bag that has been cleaned with Alconox solution to hold 
the parts; fill remainder of sonicator chamber with DI H2O to cover Ziploc bags) 
2. Rinse contents of Ziploc bag with Ti pieces or plastic parts in DI H2O 30 times 
3. Sonicate again 2 cycles of 480 seconds in DI water in the same bag. 
4. Rinse with a few more liters of DI H2O in same Ziploc bag. 
5. Let dry in Laminar flow head to prevent dust settling on surface. 
6. Mark parts with the date as “cleaned” and store in conical tubes. 
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A.5  Protocol for Paraformaldehyde Preparation 
Making Fresh Paraformaldehyde (3.7%) Solution 
(This protocol yields 100ml of formaldehyde that can be stored in the refrigerator for up 
to two weeks.) 
Equipment/Reagents: 
 Paraformaldehyde, PBS (10X without Ca and Mg), distilled water. 
 Pipettes, Erlenmeyer flask (about 100ml), graduated cylinders (10ml & 
100ml), ice in bucket, 50ml Steriflip filters or similar. 
 Hot plate/stirrer and bar, pH meter (1N HCl and 1N NaOH). 
 
Reminders: 
 Paraformaldehyde vapors are extremely toxic.  Keep under the hood as 
constantly as possible, and only heat under the hood. 
 
Protocol: 
1. Weigh out 3.7g of paraformaldehyde. 
2. Into the hood, bring the PBS, paraformaldehyde, water, NaOH, and hot 
plate/stirrer. 
3. Into a clean Erlenmeyer flask (100ml), add 10ml of PBS and about 90ml 
water. 
4. Place flask on hot plate/stirrer.  Turn on stirrer and set heat at about 55-
60C. 
5. Add paraformaldehyde to PBS, avoiding fumes. 
6. Add 20l of 1N NaOH to the solution. 
7. Allow to stir.  When nearly dissolved, remove from heat and put on ice. 
a. Note: it has been our experience that this dissolves poorly and a 
fair amount of solid will remain in the flask – the liquid should be 
poured off and the solid disposed of by vigorous rinsing into the 
formaldehyde waste container. 
8. Calibrate pH meter and adjust pH of the solution to 7.2-7.4 by adding 1N 
HCl or 1N NaOH while stirring. 
9. Return solution to hood and sterilize if desired, using a Steriflip filter (or 
similar filter device) into large conical tubes. 
10. Label tube and refrigerate (4C). 
11. Clean area and equipment. 
  
 161 
A.6  Protocol for Stent Seeding 
The below protocol is for the in-catheter seeding of delivery systems which have been 
specially designed with holes or apertures over the stent area, with endothelial cells. 
 
Supplies/Equipment:  
 Loaded delivery system (gas sterilized if for long-term [>4hr] experiment) 
 Cells (recommend 2xT75 to have enough to seed and replate) 
 Trypsin and TNS 
 DPBS (-/-) and DPBS (+/+), both sterile 
 Cell Tracker Orange (CTO) or Cell Tracker Green (CTG) 
 Serum Free Medium – EBM-2+EGM-2 
 Serum Medium – EGM-2+EGM-2+A/A;  +2% PS (for pEPC) or 2/10% FBS (for 
CBEPC) 
 Syringe Pump 
 Syringes (3cc, 5 or so) 
 For flow: Tygon tubing (5/32” ID, McMaster-Carr Item 5114K15), long enough 
for stent + entrance length 
 For flow: 2 ea. 2-way stopcocks, with male luer – to – barb adapters (see last 
photo below) 
 Flow loop [with two pulse dampeners and larger reservoir, 250 mL] if 
completing flow experiment  
Other Supplies: 
-Lab tape & timer 
-Hemacytometer 
 
A.  Cell Tracker Staining : 
1. Note:  Either Cell Tracker Orange or Cell Tracker Green may be used.   
2. To make CTO 1mM stock solution, thaw vial of 50mg aliquot in light-protected 
container in hood and add 90 uL of sterile DMSO to vial.  
3. For CTO already made, thaw CTO to room temperature by placing under hood 
in light-protected conical tube or otherwise protected from light. 
4. Warm up serum free medium (6 mL per T-75) 
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5. Turn off fluorescent light in hood 
6. To prepare CTO staining medium, aliquot 6mL serum free media for each T-75 
and 12 mL for each T-150 flask to be stained. 
7. Add 2 uL CTO solution per 1mL of serum free medium to be used.   
a. Note: Serum free media is needed because serum media would 
cleave/interfere with CTO 
8. When CTO-medium is warm, aspirate regular medium off of cells and rinse 
twice with sterile DPBS (+/+ or -/-), about 1 minute per rinse. 
9. Add specified volume CTO-media mix to cells and incubate at 37*C for 15 
minutes 
B.  Delivery System Preparation : 
1. Open sterile delivery system pouch inside the hood.  If sterilized, tray substitutes 
as a bit of a sterile field towel; use care not to touch it more than is necessary. 
2. Plug the distal end of delivery system as appropriate: 
a. For new delivery system with tip attached, use apparatus with rubber o-
rings and screw it tightly, centered over the tip-sheath transition.  Device 
can be autoclaved or sprayed/submerged in ethanol. 
 
b. For a re-utilized delivery system with tip cut off, cover sheath end with 
vinyl cap (McMaster #9753K11).  This should ideally be done before 
sterilization.  Care must be used not to damage end of sheath; cap can be 
slightly pre-stretched with SS mandrels. 
 
3. Label a 3cc syringe for ethanol and fill it with 70% ethanol.  Label a 3cc syringe 
for DPBS and fill it with sterile DPBS (+/+).  Note: this should be done carefully to 
not contaminate DPBS bottle, perhaps from a conical of aliquoted DPBS. 
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4. Gently flush delivery system with full volume of 70% ethanol, into side flushing 
port (photo below).  Liquid should be seen exiting in the stent area, and only 
minimally around sealing devices.  Do not use excessive force, or vinyl caps may 
“blow off” the end.  Flushing may be slow but is necessary to remove air pockets 
from inside delivery system. 
 
5. Following, flush delivery system with at least 1-1.5 cc of the sterile DPBS to 
replace ethanol.   Submerge delivery system end in conical of DPBS (+/+) until 
stent seeding to prevent reintroduction of air. 
 
C.  Syringe Pump Preparation: 
1. Place syringe pump into hood at far left side, plug in somewhere and turn on via 
switch at back.   
a. Note: if using outlet inside hood, “receptacle” switch atop hood must be 
switched on. 
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2. Press [Enter] to stop flashing.  Press [Set] then [Diameter] and enter syringe 
diameter:  8.66 mm for 3 mL syringe.  Press [Enter]. 
a.   (Note: if units are not as desired, press [Set] and parameter key again to 
change.) 
(http://www.harvardapparatus.com/hapdfs/HAI_DOCCAT_4/Syringe%2
0Selection%20Guide.pdf) 
3. Press [Set],  [Infuse Rate] and enter desired rate, then press [Enter] 
a. 0.4 mL/min to infuse 2 mL over 5 minutes. 
4. Press [Set],  [Refill Rate] and enter desired rate, then press [Enter] 
a. 5 mL/min or more is fine, this just backs up pump into position if needed. 
5. Press [Set] , [Target Volume] and enter volume, then press [Enter] 
a. Probably 2 mL but can adjust up or down depending on # cells resulting 
from passaging. 
6. With an empty syringe pulled back to the appropriate target volume, set pump 
to the right distance for plunger.  Press [Infuse/Refill] and [Run/Stop] to move 
plunger holder as necessary. 
D.  Flow Loop Preparation: 
1. While cells are incubating with CTO, prepare flow loop.  Open package inside 
hood and add 150 mL of [warmed] medium to reservoir. 
2. Secure cap onto reservoir.  Ensure sampling tube and uptake tube are close to 
bottom but not flush with bottom of the reservoir.  Return tube should also be as 
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far down as possible.  Adjust tubes by pulling in/out with sterile tweezers if 
needed. 
3. Connect rigid reservoir uptake tube to first pulse dampener.  Connect two pulse 
dampeners with short section of tubing.  Connect second pulse dampener to a 
placeholder connector, and connect the placeholder connector to tubing 
returning to reservoir (see photo below, with stent assembly in place of 
connector) 
 
4. Carefully carry flow assembly to small incubator and put tubing into roller 
pump.  Turn pump on to a low speed and ensure it is turning correct direction to 
move liquid from reservoir to first pulse dampener.    
5. Turn flow up (60-80 mL/min) and fill both pulse dampeners by inverting them 
then turning them right side up again.  Ensure flow is moving well and place 
paper towels beneath connector piece where stent will go.  Turn flow back down 
to 15 mL/min or so. 
E.  Passaging & Stent Seeding: 
1. While cells are incubating with CTO, warm trypsin (.025%) and TNS (will need 4 
mL trypsin per T-75 and 8mL TNS per T-75). 
2. Prepare other equipment – clean hemacytometer & coverslip as well as P20 pipet 
and place in hood. 
3. When 15 minute incubation of cells with CTO is complete, turn off fluorescent 
hood light and retrieve cells. 
4. Aspirate off media with CTO and rinse cells twice with DPBS (-/-) 
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a. Note: Approx. 30 sec. each rinse; 6 mL will cover T-75 and 12 mL will 
cover T-150.  DPBS (-/-) is done with use after this. 
5. Add trypsin to cells in volumes stated above; Place flask in incubator for 3 
minutes. 
6. At 3 minutes, take flasks out and knock against bench.  Look at cells under 
microscope to be sure that cells are detached and floating; if they are not, allow 
to incubate for another minute or so. 
7. In hood, quickly add appropriate volumes of TNS to each flask. 
8. Pipet the trypsin/TNS solution up and down and each flask and squirt it against 
the bottom surface of the flask a few times to detach any remaining adherent 
cells. 
9. Pipet all solution in each flask up and place into 50mL conical tube for centrifuge. 
10. Pipet solution up and down quickly to mix and then squirt 10uL of cell solution 
into one side of hemacytometer, change pipet tip, and repeat for the other side of 
hemacytometer. 
11. Check volume of solution in conical tube for use in cell count, and then 
centrifuge cells (1400 RPM, 5 minutes) with appropriate counterbalance. 
12. While cells are spinning, complete cell count as follows: 
a. Count one side (4 sets of 4x4 boxes) then count the other side.  Add all 
together and divide by 8, multiply by 10000, then multiply by volume of 
liquid (mL) in the conical tube.  This is the number of cells in conical. 
13. When centrifuge cycle is over, remove cells and counterbalance from centrifuge, 
being careful not to disturb pellet at bottom of conical.  
a. Note: Cells are still stained with CTO so be conscious to protect cells from 
excess light when reasonably possible. 
14. In hood, gently aspirate supernatant solution by tilting the tube and aspirating 
liquid, not disturbing cell pellet. 
28. Based on cell count, add appropriate amount of DPBS (+/+) to reach 
desired cell concentration.  Pipet up and down to mix cells well into 
suspension.  We use DPBS instead of medium as in normal passaging, 
because it seems to increase quick adhesion. 
15. Note: typical seeding density has been 1-2M/mL;  Resuspend such that final 
volume matches or exceeds that input to the syringe pump previously. 
16. Pipet appropriate volume of cell suspension into open syringe barrel with cap 
attached.  Leave any remainder of cell suspension for replating a few steps later. 
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17. Insert plunger back into open end of syringe as far as possible.   
a. Note:  If possible, gently push plunger until it passes a ridge and snaps 
back into place – it is easier to do this while capped to avoid squirting out 
cell solution. 
18. Turn syringe open-end-up and remove black cap.  Slowly advance plunger with 
cell solution until cell solution can be seen coming out top with no bubbles.  
Continue advancing plunger until cell solution forms a nice bead at top, and 
attach syringe to add to delivery system sideport previously used for flushing. 
19. Put syringe into syringe pump and carefully hold stent delivery system next to 
syringe pump. 
a. Place distal end of delivery system into a large conical to capture 
flowthrough solution, for minimal mess as well as optional counting or 
replating. 
20. Check that syringe pump is set to “INFUSE.”  If set to “REFILL” press 
[Infuse/Refill].  Once syringe is fit into plunger mechanism, press [Run/Stop] to 
begin infusion.   Hold onto bulky stent system handle so that it does not “flop” 
out of machine along with the syringe. 
21. After syringe pump has stopped, syringe may be removed from pump but 
should remain attached to stent delivery system.  Allow delivery system to sit 
stationary for 5 minutes (for better cell attachment). 
22. After 5 minutes, seeding process is complete.  For immediate imaging, deploy 
stent into air or liquid as desired and protocol is complete.  For beginning of 
flow, deploy stent into 4mm Tygon tubing and continue: 
a. Stent should be toward one end of tubing but enough room must be left 
distal to the stent to allow 3-way stopcock to fit completely inside Tygon 
tubing (leave approx. 2 cm).   
23. Attach 3-way stopcocks to both ends of Tygon tubing, and use a syringe attached 
to one stopcock to completely fill tube with warm medium (see photo below). 
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24. When tubing is full of medium, close both stopcocks and transfer stent assembly 
into flow loop.  Stop pump and wait 5-10 seconds for pressure to equalize and 
flow to stop completely.   
25. Place stent assembly into flow circuit where placeholder connector is.  Open both 
stopcocks. 
26. Start pump again – it should be at a low flowrate (15 mL/min or so).   
27. Continue ramping the flow to the desired calculated level over the first 15 
minutes and make a note of the time zero of the experiment, flow rate, and 
record other experimental notes.  Replate any leftover cells if desired.  Clean up 
the hood and you are done! 
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A.7 Protocol for Stent Recompression & Reloading 
The below protocol is tailored to the Cordis Smart stent in dimensions but will apply to 
most 6Fr self-expanding stents and delivery systems. 
 
Supplies/Equipment:  
 Blockwise Engineering Stent Recompression Device model  RMC 
 “Transfer Tube”: Teflon/FEP tubing 1/16” (.0625”) ID x 1/8” OD (McMaster 
52355K41), cut to length 1-2 cm longer than stent of interest. 
 Compression Pushing Cannula: 17 GRW Stainless steel tubing x 12” (McMaster 
8988K416)  
 Transfer Cannula: 16 GRW Stainless steel tubing x 12” (McMaster 8988K415) 
 Stainless Steel support wires: 0.015” x 12” (McMaster 6517K64); 0.032” x 12” 
(McMaster 6517K66) 
 Empty/deployed delivery systems to transfer stents 
Procedure: 
1. Begin with an expanded/deployed stent.  Place a support wire (.015” or .032”) 
through the lumen of the stent and place it into the Blockwise stent 
recompression device.
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2. Compress handle of Blockwise device completely to pre-set positive stop (stop 
should be set at OD of 17GRW cannula).  Adjust stent position until the end of 
stent just slightly protrudes from compression jaws: this will aid in alignment of 
the transfer tube to the stent jaws. 
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3. Insert 17GRW cannula into back of jaws until it can be felt to touch the back of 
the stent.   
 
4. Position transfer tube over the eyelets slightly protruding from “front” side of 
compression jaws, and align transfer tube completely over these eyelets so that 
no segments “catch” on the outside of tubing.    
5. While maintaining constant diameter on compression lever, hold tubing tightly 
against the jaws and push the cannula from behind slowly and smoothly to 
advance stent into transfer tube.   
Note: 2 operators / 3 hands may be preferred at this point.  One operator can 
hold down lever with an elbow or knee while holding the transfer tube and 
pushing cannula with opposite hands. 
 
6. When stent is completely inside tube, compression lever may be released and the 
stent removed.  The stent will now be completely contained inside the transfer 
tube.  Stents may be stored in this configuration before reloading into delivery 
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systems.  Stent should be inspected to make sure struts are not crossed, bent, or 
damaged. 
 
 
7. Select and prepare empty delivery system for stent transfer: 
a. Select a delivery system made for a stent of equal or greater length than 
the stent you wish to load.  Stents longer than that of the original delivery 
system will not “fit.” 
b. Cut off the atraumatic tip of the delivery system just proximal to that tip. 
 
8. Using the delivery system handle, extend the “inner catheter” of the delivery 
system approximately the length of the stent to be loaded.   
a. Using 17GRW or 16GRW cannula, gently advance stent so that a partial 
segment is extending from the transfer tube.  As before, this will help to 
align the stent inside the delivery system for loading.  (See photo). 
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9. Gently insert the inner catheter (orange) through the open lumen of the stent.  
Take care not to catch the end of the inner catheter on any stent struts.  Insert 
catheter in the direction shown above such that the stent struts extending from 
the transfer tube are next to the delivery sheath. 
 
 
10. Gently insert the stent struts under and inside the end of the delivery system.  
The blue material is fragile and easily damaged, so this step must be done 
cautiously!  Repeated damage will prevent delivery system from being reloaded 
at all.  Following this step, the transfer tube should be abutted to delivery system 
sheath as in the photo below. 
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11. Using the 16GRW cannula (17GRW cannula cannot fit over the orange inner 
catheter), gently advance the stent into the delivery system.  The transfer tube 
must be held tightly against the delivery sheath or segments will “escape” and 
expand, requiring stent compression to begin again at step 1. 
a. Note: For additional support, a 0.032” wire may be placed within the 
lumen of the orange inner catheter, but only if the catheter lumen has not 
been previously glued shut (see Appendix:  Preparing Delivery System 
for Re-Use) 
 
 
 
12. The stent is now fully inside the delivery system and can be deployed again. 
 
 
I. Appendix: Preparing Delivery System for Re-Use 
Supplies/Equipment:  
 Superglue 
 Luer lock needle Size 20 ½ G or smaller (larger gauge #) 
 1cc syringe  
Procedure: 
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1. To re-use a delivery system for seeding, the tip is cut off as shown above.  
Therefore it is necessary to plug both the inner catheter, and the distal end of the 
outer sheath for seeding.  The outer sheath will be capped with a small vinyl cap, 
but the inner catheter should be plugged with glue or something similar. 
2. Prepare delivery system for re-use by cutting off tip as shown above and fully 
extending inner catheter out past outer sheath. 
3. Carefully attach luer needle to 1cc syringe and uncap.  Uncap superglue and 
insert needle into superglue tip far enough so that glue can be drawn into the 
syringe through the needle. 
4. Draw up a small volume of glue (0.3 cc or less) and remove needle from glue.  
Quickly and carefully insert needle into the lumen of orange inner catheter.  
Depress syringe to place glue into inner catheter lumen.  Withdraw needle. 
5. Before glue dries (very quick), wipe the outside of the inner catheter with a 
Kimwipe or paper towel to remove excess glue.  Excess glue on the outside will 
create problems when trying to thread inner catheter through a compressed 
stent. 
6. Glue should be seen inside translucent inner catheter as one or more bubbles or 
beads.  Cyanoacrylates cure in the presence of air & moisture, which is limited 
inside the small space; catheter should be allowed to sit several hours or ideally 
overnight before use in seeding or even reloading.   
7. Important – mark that the ‘inner catheter has been glued’ on delivery system 
handle to identify this.  Gluing will not have to be repeated if catheter is re-used 
again. 
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